Australian Broker Call
Produced and copyrighted by
at www.fnarena.com
August 19, 2026
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1).
Last Updated: 05:00 PM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
Today's Upgrades and Downgrades
| AHL - | Adrad | Upgrade to Buy from Hold | Bell Potter |
| AUC - | Ausgold | Downgrade to Speculative Hold from Speculative Buy | Bell Potter |
| BEN - | Bendigo & Adelaide Bank | Downgrade to Hold from Accumulate | Ord Minnett |
| BHP - | BHP Group | Downgrade to Trim from Hold | Morgans |
| BSL - | BlueScope Steel | Downgrade to Neutral from Outperform | Macquarie |
| COH - | Cochlear | Upgrade to Neutral from Sell | Citi |
| HUB - | Hub24 | Downgrade to Hold from Buy | Bell Potter |
| IMD - | Imdex | Upgrade to Buy from Hold | Ord Minnett |
| LLC - | Lendlease Group | Downgrade to Neutral from Buy | Citi |
Overnight Price: $1.65
Macquarie rates AEL as Outperform (1) -
Amplitude Energy has confirmed circa 80% of its legacy gas production is contracted in 2026.
Recent contracts with AGL Energy ((AGL)) and Energy Australia have been well timed, Macquarie suggests, and reflect the prudent approach of steadily engaging high-quality, well-capitalised customers over time and de-risking the project.
The latest gas market interventions drive a structural oversupply in domestic gas markets, but Macquarie believes incentives may ultimately be required to encourage investment in backfill supply projects (e.g. carve-outs, subsidies, creation of domestic trading credit market).
Outperform retained, target rises to $2.45 from $2.15.
Target price is $2.45 Current Price is $1.65 Difference: $0.805
If AEL meets the Macquarie target it will return approximately 49% (excluding dividends, fees and charges).
Current consensus price target is $2.63, suggesting upside of 60.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 16.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.6, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 9.3. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 0.00 cents and EPS of 22.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.5, implying annual growth of 39.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 6.7. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates AEL as Buy (1) -
Ord Minnett maintains Amplitude Energy on Buy and cuts its target to $2.55 from $2.65. FY26 operating EBITDA of $198m was broadly in line, while adjusted NPAT reached $100m with support from tax benefits.
FY27 guidance of 26.6–28.5PJ, costs of $58–64m and capex of $250m–$310m are all considered solid.
The broker expects production to grow 60% by FY30, with September's Juliet drilling result and a potential Nestor option exercise the key catalysts.
Forecasts incorporate the result and guidance, including slightly lower production, higher costs and greater capex than previously assumed.
Target price is $2.55 Current Price is $1.65 Difference: $0.905
If AEL meets the Ord Minnett target it will return approximately 55% (excluding dividends, fees and charges).
Current consensus price target is $2.63, suggesting upside of 60.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of 14.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.6, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 9.3. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 0.00 cents and EPS of 26.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.5, implying annual growth of 39.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 6.7. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AHL ADRAD HOLDINGS LIMITED
Automobiles & Components
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.22
Bell Potter rates AHL as Upgrade to Buy from Hold (1) -
Bell Potter upgrades its rating for Adrad to Buy with its target price increased to $1.40 from $1.35 following the release of a "sound" FY26 financial result.
Underlying EBITDA grew 10% to $19.5m, matching the broker's estimates, while statutory EBITDA outperformed expectations due to a lower incentive accrual.
The analyst highlights a stronger-than-expected cash position of $24.5m alongside a higher final dividend payout of 2.56c.
Management indicates business positioning supports a stronger half-year result compared to the previous corresponding period, underpinned by a substantial order book.
The analyst raises the valuation multiple following the solid performance, signalling confidence in ongoing operational execution.
Target price is $1.40 Current Price is $1.22 Difference: $0.185
If AHL meets the Bell Potter target it will return approximately 15% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 4.70 cents and EPS of 10.00 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 5.30 cents and EPS of 10.90 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AIA AUCKLAND INTERNATIONAL AIRPORT LIMITED
Travel, Leisure & Tourism
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.25
Citi rates AIA as Neutral (3) -
Citi highlights a strong start to FY27 for Auckland International Airport, with July international passengers rising 5% year-on-year.
International growth was supported by US and Chinese passengers, while domestic traffic fell -2% and remains -13% below pre-Covid levels, the analysts explain.
The broker forecasts FY27 international passenger growth of around 3% and a -2% domestic decline, with new passenger and EPS guidance due at FY26 results.
Citi likes the medium-term earnings potential from Auckland Airport's -NZ$6bn-plus capex program but sees near-term risks from Air New Zealand ((AIZ)) capacity and weaker economic sentiment.
Neutral rating. Target NZ$8.80.
Current Price is $7.25. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 11.31 cents and EPS of 15.64 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.1, implying annual growth of N/A. Current consensus DPS estimate is 10.8, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 48.9. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 12.16 cents and EPS of 15.98 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.7, implying annual growth of 4.0%. Current consensus DPS estimate is 11.3, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 47.0. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates APA as Buy (1) -
Citi highlights APA Group's attractive free cash flow (FCF) yield and growth outlook ahead of FY26 results on 20 August.
The broker points to an around 8% FCF yield and expects annual FCF growth above 3% through FY30.
Growth is expected to be supported by the group's -$3bn capex pipeline and CPI-linked escalation, with the analysts seeing upside to current valuation metrics.
Citi retains its Buy rating and target of $11.10.
Target price is $11.10 Current Price is $10.01 Difference: $1.09
If APA meets the Citi target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $9.44, suggesting downside of -6.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 58.00 cents and EPS of 16.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.3, implying annual growth of 139.5%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 55.2. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 59.00 cents and EPS of 20.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.5, implying annual growth of 28.4%. Current consensus DPS estimate is 59.0, implying a prospective dividend yield of 5.8%. Current consensus EPS estimate suggests the PER is 43.0. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.38
Bell Potter rates APZ as Buy (1) -
Bell Potter maintains a Buy rating for Aspen Group with its target price increased to $6.65 from $6.50 following a solid FY26 result and an upgraded FY27 outlook.
Underlying operating EPS landed at 21.8c, beating guidance and meeting expectations. Management upgraded FY27 EPS guidance to 26.1c alongside an established dividend of 12.0c.
The analyst highlights that development targets for FY27 increased to 240 lots while the business completed strategic portfolio recycling.
The broker's estimates adjust underlying post-tax EPS estimates by -1% to +4% over the forecast period to reflect the stronger operational trajectory.
Target price is $6.65 Current Price is $5.38 Difference: $1.27
If APZ meets the Bell Potter target it will return approximately 24% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 12.00 cents and EPS of 23.10 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 12.50 cents and EPS of 27.20 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates APZ as Buy (1) -
Citi remains positive on Aspen Group after a strong FY26 'beat' and upgraded FY27 guidance.
Underlying pre-tax EPS rose 30% to 21.8c, supported by 21% rental income growth and a 71% increase in realised development profit, the analysts explain.
The broker highlights upgraded FY27 guidance for 26.1c EPS (up 4.4%), $66m EBITDA (up 22%) and 12c DPS (up 9%), while the rental portfolio remains essentially fully occupied.
Aspen's affordability-focused model and conservative 22% loan-to-value (LTV) ratio is expected to provide downside protection.
Buy rating. Target of $6.10.
Target price is $6.10 Current Price is $5.38 Difference: $0.72
If APZ meets the Citi target it will return approximately 13% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.33
Bell Potter rates AUC as Downgrade to Speculative Hold from Speculative Buy (3) -
Bell Potter downgrades its recommendation for Ausgold to Speculative Hold with its valuation decreased to $1.50 following an acquisition agreement with OceanaGold.
OceanaGold agreed to acquire 100% of Ausgold shares via a Scheme of Arrangement representing an implied offer value of $1.36 per share.
The analyst highlights that shareholders will gain exposure to operating assets while retaining exposure to the Katanning development upside.
The broker's estimates and valuation reflect a 10% premium to the initial offer price, recognising the company being in-play.
The board unanimously recommends the scheme in the absence of a superior offer.
Target price is $1.50 Current Price is $1.33 Difference: $0.175
If AUC meets the Bell Potter target it will return approximately 13% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.40 cents. |
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.30 cents. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $10.56
Citi rates BEN as Sell (5) -
Citi notes Bendigo & Adelaide Bank announced APRA has imposed licence conditions relating to non-financial risk, requiring a broader rectification plan and an independent reviewer, with the program estimated to cost -$70m and taken upfront in FY26.
This adds to existing anti-money-laundering and cyber issues, increasing the execution risk as the bank also integrates RACQ and pursues strategic technology partnerships.
The analyst lifts its FY26 cash earnings forecast by around 3% but cuts FY27 by around -14%, partly reflecting -$100m–$123m of one-offs moving above the line as notable items under a change in financial reporting.
There is higher execution risk for FY27, Citi warns, as the bank manages its regulatory program alongside volume and margin pressures in a slowing environment. Sell rated. Target $10.
Target price is $10.00 Current Price is $10.56 Difference: minus $0.56 (current price is over target).
If BEN meets the Citi target it will return approximately minus 5% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $10.22, suggesting downside of -1.8% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 81.9, implying annual growth of N/A. Current consensus DPS estimate is 62.9, implying a prospective dividend yield of 6.0%. Current consensus EPS estimate suggests the PER is 12.7. |
Forecast for FY28:
Current consensus EPS estimate is 78.8, implying annual growth of -3.8%. Current consensus DPS estimate is 63.3, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates BEN as Underperform (5) -
In response to APRA's imposition of licencing conditions, Bendigo & Adelaide Bank has announced a -$70m three-year rectification plan to improve non-financial risk, Macquarie reports.
Meanwhile, the bank delivered a better 2H26 result, 5% above consensus, underpinned by better other income (Homesafe) and cost management.
While the operational performance in 2H26 was better, a return on equity capped at 7%, a challenging sector backdrop as credit growth slows and competition increases, and ongoing execution risks as the bank works through a significant regulatory uplift mean Macquarie maintains Underperform.
Target unchanged at $9.00.
Target price is $9.00 Current Price is $10.56 Difference: minus $1.56 (current price is over target).
If BEN meets the Macquarie target it will return approximately minus 15% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $10.22, suggesting downside of -1.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 63.00 cents and EPS of 87.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 81.9, implying annual growth of N/A. Current consensus DPS estimate is 62.9, implying a prospective dividend yield of 6.0%. Current consensus EPS estimate suggests the PER is 12.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 63.00 cents and EPS of 79.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 78.8, implying annual growth of -3.8%. Current consensus DPS estimate is 63.3, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates BEN as Underweight (5) -
Bendigo & Adelaide Bank's unaudited 2H26 result was largely as expected, Morgan Stanley notes, but slightly better than consensus.
APRA has instituted licence conditions on the bank due to "longstanding and pervasive" weakness in its non-financial risk management. The new rectification plan is expected to cost -$70m pre-tax on top of AUSTRAC's -$50m capital add-on and the ongoing investigation.
Cash profit for 2H was better than consensus while expenses were broadly in line.
Target price unchanged at $9.80 with an Underweight rating.
Industry view: Cautious.
Target price is $9.80 Current Price is $10.56 Difference: minus $0.76 (current price is over target).
If BEN meets the Morgan Stanley target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $10.22, suggesting downside of -1.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 64.00 cents and EPS of 71.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 81.9, implying annual growth of N/A. Current consensus DPS estimate is 62.9, implying a prospective dividend yield of 6.0%. Current consensus EPS estimate suggests the PER is 12.7. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 64.00 cents and EPS of 81.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 78.8, implying annual growth of -3.8%. Current consensus DPS estimate is 63.3, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates BEN as Downgrade to Hold from Accumulate (3) -
Ord Minnett downgrades Bendigo and Adelaide Bank to Hold from Accumulate, lowers its target to $11.00 from $11.50 and raises the risk rating to Higher from Medium.
Commentary explains APRA has imposed licence conditions over persistent non-financial risk-management weaknesses and retained a $50m operational-risk capital add-on, prompting a three-year, -$70m remediation program.
Preliminary second-half cash NPAT of $273.8m was approximately 5% above consensus and net interest margin improved 6bps to 1.98%, but remediation could divert resources from the technology and growth agenda, the broker warns.
EPS forecasts change by 4.5%, -6.7% and 2.1% for FY26-FY28 respectively; regulatory remediation and pressure on the bank's 10% return-on-equity target are seen as the major risks.
Target price is $11.00 Current Price is $10.56 Difference: $0.44
If BEN meets the Ord Minnett target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $10.22, suggesting downside of -1.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 63.00 cents and EPS of 87.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 81.9, implying annual growth of N/A. Current consensus DPS estimate is 62.9, implying a prospective dividend yield of 6.0%. Current consensus EPS estimate suggests the PER is 12.7. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 63.00 cents and EPS of 76.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 78.8, implying annual growth of -3.8%. Current consensus DPS estimate is 63.3, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $63.85
Macquarie rates BHP as Neutral (3) -
BHP Group reported FY26 earnings per share up 4%, marginally above consensus. Macquarie highlights a 6% free cash flow beat with asset sales proceeds driving a 22% final dividend beat.
Looking forward, Macquarie suggests one could expect a more cash flow-oriented approach to dividends (versus an earnings-based pay-out ratio) with prices running above long-term.
BHP's share price has continued its strong run as investors seek to gain exposure to copper, but given the broker's forecast 2-5% yield across FY27-29, either continued commodity price support or increased productivity driven growth may be required to support valuations.
Neutral retained, target rises to $58.50 from $55.00.
Target price is $58.50 Current Price is $63.85 Difference: minus $5.35 (current price is over target).
If BHP meets the Macquarie target it will return approximately minus 8% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $61.05, suggesting downside of -4.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 207.12 cents and EPS of 345.68 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 396.0, implying annual growth of N/A. Current consensus DPS estimate is 216.7, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 204.20 cents and EPS of 339.85 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 387.6, implying annual growth of -2.1%. Current consensus DPS estimate is 237.7, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 16.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates BHP as Overweight (1) -
Morgan Stanley analysts highlight that BHP Group announced a robust final DPS, which beat their forecast by 3% and consensus by 10%. FY26 EPS was in line with the forecast, but above consensus by 5%.
Net debt was a beat and underlying net profit after tax was also better than anticipated.
The analysts point to BHP's expanding organic copper growth pipeline, with larger projects at Escondida and potential block caving at Olympic Dam, while management continues to favour organic growth over M&A given substantially lower capital intensity.
The broker also points to further productivity gains from BHP Operating System and technology initiatives.
Overweight rating. Target $67.50. Industry view: Attractive.
Target price is $67.50 Current Price is $63.85 Difference: $3.65
If BHP meets the Morgan Stanley target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $61.05, suggesting downside of -4.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 373.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 396.0, implying annual growth of N/A. Current consensus DPS estimate is 216.7, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 371.94 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 387.6, implying annual growth of -2.1%. Current consensus DPS estimate is 237.7, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 16.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates BHP as Downgrade to Trim from Hold (4) -
BHP Group's FY26 underlying EBITDA of US$32.9bn, up 27%, was 4% ahead of Morgans forecast, while underlying NPAT of US$13.2bn was 12% better than expected.
The USD99c final dividend, which lifted FY26 DPS to USD172c, was supported by free cash flow of US$9.8bn and net debt falling to US$8.7bn.
Copper drove 84% of group earnings growth, largely due to higher copper and by-product prices; the analyst also highlights strong operating performances at Escondida and WAIO.
Morgans remains positive on BHP's capital discipline and copper growth options but believes the share price already factors in further upside.
The stock is downgraded to Trim from Hold with a lower target of $55.30 from $60.20.
Target price is $55.30 Current Price is $63.85 Difference: minus $8.55 (current price is over target).
If BHP meets the Morgans target it will return approximately minus 13% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $61.05, suggesting downside of -4.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 217.33 cents and EPS of 363.19 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 396.0, implying annual growth of N/A. Current consensus DPS estimate is 216.7, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 221.70 cents and EPS of 369.02 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 387.6, implying annual growth of -2.1%. Current consensus DPS estimate is 237.7, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 16.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates BHP as Hold (3) -
Ord Minnett maintains BHP Group on Hold and lifts its target to $63.00 from $61.00 following the FY26 result release.
Underlying EBITDA increased 27% to US$32.9bn and NPAT rose 30% to US$13.2bn, while the US99c final dividend beat the US83c consensus forecast and net debt fell to US$8.7bn.
Copper generated almost 55% of group EBITDA, but nearer-term copper-equivalent production is expected to decline as Escondida grades fall, while medium-term annual capex guidance rises to around US$11bn. FY27–FY29 earnings forecasts fall -5.2%, -1.8% and -0.4% respectively.
Ord Minnett prefers Rio Tinto ((RIO)) due to its stronger near-term growth, higher yield and lower valuation multiple.
Target price is $63.00 Current Price is $63.85 Difference: minus $0.85 (current price is over target).
If BHP meets the Ord Minnett target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $61.05, suggesting downside of -4.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 313.59 cents and EPS of 532.38 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 396.0, implying annual growth of N/A. Current consensus DPS estimate is 216.7, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 309.22 cents and EPS of 517.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 387.6, implying annual growth of -2.1%. Current consensus DPS estimate is 237.7, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 16.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BRE BRAZILIAN RARE EARTHS LIMITED
Rare Earth Minerals
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.30
Ord Minnett rates BRE as Speculative Buy (1) -
Ord Minnett maintains its Speculative Buy rating and its $6.50 target after Brazilian Rare Earths reissued the Rocha da Rocha scoping study excluding Sulista's inferred resources.
The broker keeps Sulista in its valuation model at an indicative 10Mt, arguing the regulatory change does not alter the project's development potential or the planned Salvador refining hub.
The next catalysts are permitting, the prefeasibility study, further Sulista drilling and metallurgical testing for titanium, niobium, tantalum and scandium by-products.
Forecasts and valuation are unchanged.
Target price is $6.50 Current Price is $4.30 Difference: $2.2
If BRE meets the Ord Minnett target it will return approximately 51% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY26:
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 14.30 cents. |
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 14.70 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BRG BREVILLE GROUP LIMITED
Household & Personal Products
More Research Tools In Stock Analysis - click HERE
Overnight Price: $33.10
Citi rates BRG as Buy (1) -
The key takeaway from the conference call is that FY27 is in a better position to grow earnings versus FY26. Lower tariffs from the new manufacturing base should support margins, while young markets are highlighted by Citi as scaling.
Notably, the premium consumer remains resilient, which is the major factor against a backdrop of ongoing risks from tariff volatility to the Middle East war.
Following today's FY26 result by Breville Group, Citi's first impression is that its structural growth thesis remains intact despite continued pressure on earnings conversion and margins.
FY26 earnings (EBIT) of $207m were in line with consensus, while second-half gross margin improved to 36.8% from 35.4% in H1 and net cash increased to $104.4m from $48.5m, the analysts highlight.
Citi sees espresso, geographic expansion and solutions/services supporting growth, while M&A provides further upside given the strong balance sheet.
As per usual practice, no FY27 guidance was provided.
Target $39.65. Buy.
Target price is $39.65 Current Price is $33.10 Difference: $6.55
If BRG meets the Citi target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $37.48, suggesting upside of 19.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 37.70 cents and EPS of 93.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 94.0, implying annual growth of -0.5%. Current consensus DPS estimate is 38.3, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 33.4. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 40.90 cents and EPS of 101.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 106.5, implying annual growth of 13.3%. Current consensus DPS estimate is 42.2, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 29.5. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates BRG as Buy (1) -
First Take: Breville Group delivered FY26 EBIT in line with UBS and consensus, as weaker revenue growth was offset by better gross and EBIT margins, while strong cash flow helped the company finish with $104m net cash.
No FY27 guidance was provided, although the analyst sees company-specific tailwinds from new products, geographic expansion and store-in-store growth, balanced against tariff and cost uncertainty.
Target $36. Buy.
Target price is $36.00 Current Price is $33.10 Difference: $2.9
If BRG meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $37.48, suggesting upside of 19.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 39.00 cents and EPS of 94.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 94.0, implying annual growth of -0.5%. Current consensus DPS estimate is 38.3, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 33.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 42.00 cents and EPS of 105.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 106.5, implying annual growth of 13.3%. Current consensus DPS estimate is 42.2, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 29.5. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $31.50
Macquarie rates BSL as Downgrade to Neutral from Outperform (3) -
BlueScope Steel's FY26 underlying earnings increased 73%, led by stronger US spreads and record Southeast Asian earnings. Australian Steel Products missed, Macquarie notes, but demand is robust.
Market conditions in the US are strong, but persistence is a key question for the broker. The prospect of material further improvement seems remote, given extreme US versus Asia hot rolled coil (HRC) price dynamics.
Execution has been strong, with a planned cost-out now expected to yield $150m in net benefits in FY27. However the stock trades at a near term enterprise value to earnings multiple of 9.7x, a 25% premium to its ten-year average.
Macquarie thus downgrades to Neutral from Outperform. Target falls to $34.35 from $35.95.
Target price is $34.35 Current Price is $31.50 Difference: $2.85
If BSL meets the Macquarie target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $33.71, suggesting upside of 4.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 130.00 cents and EPS of 302.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 266.1, implying annual growth of 45.4%. Current consensus DPS estimate is 172.5, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 130.00 cents and EPS of 307.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 258.9, implying annual growth of -2.7%. Current consensus DPS estimate is 133.3, implying a prospective dividend yield of 4.1%. Current consensus EPS estimate suggests the PER is 12.4. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates BWP as Buy (1) -
In an initial assessment of today's FY26 result by BWP Trust, Citi points to a broadly in-line outcome with the REIT's strategic reset improving portfolio quality and balance sheet flexibility.
Management internalisation, completed in August 2025, better aligned management with securityholder interests and reduced the management expense ratio from 0.66% to 0.34%, the broker explains.
The Bunnings lease reset extended the weighted average lease expiry (WALE) to 7.3 years from 4.5 years, while gearing declined to 18.5% from 21.6%, the analyst explains.
FY27 DPU guidance of 20c implies to the broker around 3% growth, slightly above consensus.
BWP Trust trades at an -8.8% discount to net tangible assets (NTA) of $4.11, which Citi considers attractive following the platform reset.
Buy. Target $4.
Target price is $4.00 Current Price is $3.75 Difference: $0.25
If BWP meets the Citi target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $4.00, suggesting upside of 5.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 19.40 cents and EPS of 19.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.3, implying annual growth of -48.0%. Current consensus DPS estimate is 19.2, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 19.7. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 19.80 cents and EPS of 20.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.0, implying annual growth of 3.6%. Current consensus DPS estimate is 19.8, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 19.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates BWP as Neutral (3) -
First Take: Improving rental growth and a stronger balance sheet underpinned BWP Trust's broadly in-line FY26 result, with like-for-like rental growth rising to 3% from 2.6% at 1H26, occupancy reaching 98.4% and NTA increasing to $4.11 from $4.00.
UBS notes continued progress on the large format retail strategy, including the $25.2m acquisition of Sunbury Lifestyle Centre at a 6% cap rate, while key developments remain on track at attractive yields.
Gearing declined to 18.5% from 24.7%, although the cost of debt increased to 4.6% and lower hedging over coming years remains a headwind. FY27 DPU guidance of 20c is around 1.5% above UBS and consensus.
Neutral. Target $3.89.
Target price is $3.89 Current Price is $3.75 Difference: $0.14
If BWP meets the UBS target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $4.00, suggesting upside of 5.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 19.00 cents and EPS of 19.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.3, implying annual growth of -48.0%. Current consensus DPS estimate is 19.2, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 19.7. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 20.00 cents and EPS of 20.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.0, implying annual growth of 3.6%. Current consensus DPS estimate is 19.8, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 19.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CGF CHALLENGER LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $10.32
Citi rates CGF as Buy (1) -
Following FY26 results, Citi views a marked reduction in capital intensity at Challenger as a potential game-changer. Favourable volume growth, EPS growth and return on equity (ROE) targets are anticipated, despite softer normalised guidance and tight spreads.
FY27-FY28 normalised EPS forecasts fall -5% and -2%, respectively, while lower capital requirements could support significant special dividends or capital returns, in the broker's view.
Citi lowers its target to $11.55 from $11.90 and retains its Buy rating.
Target price is $11.55 Current Price is $10.32 Difference: $1.23
If CGF meets the Citi target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $10.52, suggesting upside of 7.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Current consensus EPS estimate is 69.7, implying annual growth of N/A. Current consensus DPS estimate is 34.3, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 14.1. |
Forecast for FY28:
Current consensus EPS estimate is 74.5, implying annual growth of 6.9%. Current consensus DPS estimate is 39.0, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates CGF as Neutral (3) -
Challenger announced a further $300m buyback with the FY26 result, bringing the total program to $450m, with some $380m incorporated into FY27 earnings guidance. A fully franked 1.5cps special dividend was also announced which was not in consensus estimates.
Total Life book growth reached 9.2%, Macquarie reports, supported by record annuity sales, up 19%, as offshore reinsurance sales increased 25% to a record $1.2bn.
The broker nevertheless retains Neutral, believing that at current valuations, the announced capital returns and offshore growth opportunities are largely priced in, limiting near-term upside. Target falls to $10.20 from $10.30.
Target price is $10.20 Current Price is $10.32 Difference: minus $0.12 (current price is over target).
If CGF meets the Macquarie target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $10.52, suggesting upside of 7.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 32.50 cents and EPS of 68.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 69.7, implying annual growth of N/A. Current consensus DPS estimate is 34.3, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 14.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 38.00 cents and EPS of 76.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 74.5, implying annual growth of 6.9%. Current consensus DPS estimate is 39.0, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates CGF as Neutral (3) -
A softer core earnings picture emerged beneath Challenger's slightly better-than-expected FY26 result, with normalised NPAT of $468m around 1% ahead of UBS and consensus but core earnings falling -16% in 2H26 as credit spreads tightened and funding costs increased.
Life AUM reached $26.6bn, while 4Q26 Life sales rose 9% and were 12% ahead of UBS, with the broker also highlighting the increased $300m buyback and 1.5c special dividend.
FY27 core EPS (65% of FY26 EPS, equivalent) guidance of 45-49c implies a lower earnings base. The analyst forecasts FY27 EPS of 70.1c, around -7% below consensus, although Challenger's new 3%-5% year EPS CAGR target of 8%-10% supports an attractive medium-term growth outlook.
FY27-FY28 EPS forecasts are raised by around 1%, with FY30 unchanged. The broker retains Neutral and its $11.30 target.
Target price is $11.30 Current Price is $10.32 Difference: $0.98
If CGF meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $10.52, suggesting upside of 7.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 36.00 cents and EPS of 66.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 69.7, implying annual growth of N/A. Current consensus DPS estimate is 34.3, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 14.1. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 40.00 cents and EPS of 72.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 74.5, implying annual growth of 6.9%. Current consensus DPS estimate is 39.0, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 13.2. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.73
Bell Potter rates CGS as Buy (1) -
Bell Potter maintains a Buy rating for Cogstate with a $3.70 target price following a robust FY26 result featuring a strong second-half margin rebound.
Total revenue reached US$60.9m while EBITDA came in at US$18.3m, both beating the broker's estimates due to higher gross margins and clinical trials activity.
The analyst highlights that FY27 starts from a record contracted revenue base of US$118.5m, providing strong visibility for ongoing growth.
The broker's estimates factor in increased revenue expectations offset by higher operating expenses to support scaling initiatives.
Management expects to maintain annual EBITDA margins while investing in automated technology solutions across the forecast period.
Target price is $3.70 Current Price is $2.73 Difference: $0.97
If CGS meets the Bell Potter target it will return approximately 36% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 7.29 cents and EPS of 13.42 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 8.02 cents and EPS of 15.90 cents. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $141.20
Citi rates COH as Upgrade to Neutral from Sell (3) -
In the wake of Cochlear's FY26 results, Citi raises its target by $40 to $140 and upgrades to Neutral from Sell. It's felt weaker demand and healthcare system pressures are now largely reflected in expectations.
The broker expects 2H26 marked the earnings low point, while cost controls should support recovery despite profit margins remaining below the 18% target beyond FY30.
The analyst's mid-term profit growth is forecast at around 12% annually, with totally implantable devices providing potential upside to estimates.
Target price is $140.00 Current Price is $141.20 Difference: minus $1.2 (current price is over target).
If COH meets the Citi target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $131.66, suggesting downside of -4.3% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 527.8, implying annual growth of N/A. Current consensus DPS estimate is 374.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.1. |
Forecast for FY28:
Current consensus EPS estimate is 581.8, implying annual growth of 10.2%. Current consensus DPS estimate is 393.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates COH as Neutral (3) -
Cochlear's FY26 revenue and gross profit were largely in line while underlying profit was 4% above consensus, driven by lower-than-expected Selling, General and Administrative Expense, Macquarie notes.
FY27 profit guidance is in line with consensus, factoring in modest low-single-digit constant currency sales growth and slightly lower opex. Cochlear aims to return the profit margin to 18% over the medium-term from 13.7% in FY26, but no longer has a firm gross-margin target of 75%.
Modest cochlear implant growth and moderating services revenue amid gross-margin pressure and execution risk across referral pathways, evidence generation and cost control, leave Macquarie on a Neutral rating. Target rises to $124 from $115.
Target price is $124.00 Current Price is $141.20 Difference: minus $17.2 (current price is over target).
If COH meets the Macquarie target it will return approximately minus 12% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $131.66, suggesting downside of -4.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 360.00 cents and EPS of 514.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 527.8, implying annual growth of N/A. Current consensus DPS estimate is 374.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 368.00 cents and EPS of 526.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 581.8, implying annual growth of 10.2%. Current consensus DPS estimate is 393.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates COH as Equal-weight (3) -
First take: Cochlear's FY26 results were a slight beat against consensus expectations.
Morgan Stanley points to higher than forecasts CI units, above consensus by 3% and expectations by 5% with NPAT 4% higher than both forecasts. Gross margins missed and implied 66.6% in 2H26.
FY27 outlook was for low single-digit sales growth, in line with expectations and the midpoint of NPAT after-tax guidance some -6% lower than the broker's forecast. The key variable is the lower gross margin indicated by management's guidance.
Equal weight. Target $123. Industry View: In-Line.
Target price is $123.00 Current Price is $141.20 Difference: minus $18.2 (current price is over target).
If COH meets the Morgan Stanley target it will return approximately minus 13% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $131.66, suggesting downside of -4.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 413.00 cents and EPS of 556.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 527.8, implying annual growth of N/A. Current consensus DPS estimate is 374.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.1. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 646.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 581.8, implying annual growth of 10.2%. Current consensus DPS estimate is 393.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates COH as Hold (3) -
Ord Minnett maintains Cochlear on Hold and raises its target to $145.80 from $133.00 after FY26 underlying NPAT of $322m finished around 4% above consensus.
Cochlear implant unit sales grew 5%, although revenue was flat in constant currency because of a greater contribution from lower-priced emerging markets, while FY27 NPAT guidance of $330m–$350m implies subdued mid-single-digit growth.
Services growth is expected to moderate as the Nucleus 8 replacement cycle matures, with Middle East disruption, Chinese reimbursement cuts and mixed developed-market conditions constraining visibility.
FY27–FY29 EPS forecasts increase 2.3%, 3.1% and 2.3% respectively, mainly on higher implant revenue and cost reductions; longer-term underpenetration supports growth, but the near-term outlook remains muted, the report concludes.
Target price is $145.80 Current Price is $141.20 Difference: $4.6
If COH meets the Ord Minnett target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $131.66, suggesting downside of -4.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 372.00 cents and EPS of 523.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 527.8, implying annual growth of N/A. Current consensus DPS estimate is 374.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.1. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 410.00 cents and EPS of 586.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 581.8, implying annual growth of 10.2%. Current consensus DPS estimate is 393.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates COH as Neutral (3) -
On further inspection, target price is raised to $150 from $106 and Neutral rating retained. EPS forecasts are tweaked up 2% for FY27 and -1% for FY28.
EPS forecasts are tweaked higher by 2% for FY27 and down -1% for FY28.
First take: UBS's first impression is that Cochlear's FY26 release is better-than-expected, helped by cost cutting and FX gains. Management's guidance for FY27 is considered in line with consensus.
Commentary explains the outlook suggests only modest sales growth in both developed and emerging markets as current trading conditions remain mixed.
Management's guidance for flat gross margins is due to the ASP headwind in China but will be offset by a reduction in operating expenditure, the broker explains.
Overall, UBS thinks today's result will likely be "good enough" given expectations for FY27 were low.
Neutral rating and $106 target.
Target price is $150.00 Current Price is $141.20 Difference: $8.8
If COH meets the UBS target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $131.66, suggesting downside of -4.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 366.00 cents and EPS of 519.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 527.8, implying annual growth of N/A. Current consensus DPS estimate is 374.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.1. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 402.00 cents and EPS of 569.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 581.8, implying annual growth of 10.2%. Current consensus DPS estimate is 393.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CSL CSL LIMITED
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $157.82
Bell Potter rates CSL as Hold (3) -
Bell Potter maintains a Hold rating for CSL with its target price increased to $150.00 from $120.00 following the release of a FY26 result where constant currency NPATA declined -2% to $3.14bn.
The analyst highlights a solid operational rebound in Behring immunoglobulin sales alongside improving gross margin guidance of approximately 70bps for FY27.
The broker adjusts forecasts upward across FY27 to FY29 following updated underlying net profit metrics and improved guidance.
Management provides FY27 guidance for underlying net profit growth of 5% at constant currency, with commentary concluding this signals the earnings downgrade cycle has eased.
Target price is $150.00 Current Price is $157.82 Difference: minus $7.82 (current price is over target).
If CSL meets the Bell Potter target it will return approximately minus 5% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 340.00 cents and EPS of 883.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 546.97 cents and EPS of 910.15 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates CSL as Neutral (3) -
Citi believes the worst is in the past for CSL following FY26 results, with FY27 profit guidance ahead of consensus and mid-single-digit growth expected over the medium term.
FY27 profit guidance for 5% growth exceeded consensus expectations of 1%-2% constant-currency growth, prompting a 17% share price rally.
The broker expects FY27 sales to remain flat as Vifor and China albumin headwinds persist, leaving cost reductions to drive most earnings growth.
Citi forecasts 6% constant-currency profit growth in FY27, slightly above guidance, with similar growth expected over the medium term.
Target rises to $160 from $110. Neutral rating maintained.
Target price is $160.00 Current Price is $157.82 Difference: $2.18
If CSL meets the Citi target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates CSL as Neutral (3) -
CSL's FY26 earnings came in 3% above consensus driven by revenue, Macquarie reports, although a 17% higher tax bill pulled profit in line with guidance.
Compositionally, Behring was 2% ahead on revenue, while the gross margin was in line with expectations at 49.6%, which included flat IG revenue and albumin down -17% on China impacts. Seqirus and Vifor were above expectations but a smaller impact to the group.
Despite signs of stabilisation, Macquarie sees ongoing uncertainty across core business segments (IG, albumin) and medium-term competitive risks (new IG products, complement inhibitors, recombinant albumin). Neutral retained, target rises to $133 from $108.
Target price is $133.00 Current Price is $157.82 Difference: minus $24.82 (current price is over target).
If CSL meets the Macquarie target it will return approximately minus 16% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 425.90 cents and EPS of 859.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 449.24 cents and EPS of 915.99 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates CSL as Overweight (1) -
Morgan Stanley believes CSL's FY26 results vindicated the company is "back on track" with both the result and FY27 guidance pointing to an improving growth profile.
Ig revenue was up 7% in 2H26 and FY27 growth expected in line with the mid-to-high single-digit market. Volumes have stabilised in China with lower prices expected to offset revenue growth.
CSL Behring gross margin slipped -100bps but management is targeting 70bps-plus expansion in FY27. Group revenue should align in FY27 with FY26.
The analyst has raised earnings forecasts for Behring and Seqirus but lowered forecasts for Vifor. FY27 and FY28 EPS forecasts are lifted by 4% and 5%.
Retain Overweight. Target is raised to $172 from $163. Industry View: In-Line.
Target price is $172.00 Current Price is $157.82 Difference: $14.18
If CSL meets the Morgan Stanley target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 487.17 cents and EPS of 958.29 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 498.83 cents and EPS of 1023.92 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates CSL as Buy (1) -
Morgans notes CSL's FY26 revenue and underlying NPATA were broadly in line with Morgans, while cash flow remained resilient at US$3.5bn.
The broker highlights stabilising Ig demand, seasonal influenza growth at Seqirus and US$176m of transformation savings ahead of target, although Vifor remains challenged.
FY27 revenue is expected to be broadly flat as Vifor revenue falls around -25%, while Behring and Seqirus growth, cost savings and improved commercial execution are expected to support 5% NPAT growth.
FY27-FY28 NPAT forecasts moved by up to -3% lower, mainly due to weaker Vifor margins, but the analyst sees increasing confidence the cycle of earnings downgrades is ending.
Buy rated with a higher target of $187.71 from $147.59 on a multiple roll forward.
Target price is $187.71 Current Price is $157.82 Difference: $29.89
If CSL meets the Morgans target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 437.57 cents and EPS of 892.65 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 456.53 cents and EPS of 952.45 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates CSL as Hold (3) -
Ord Minnett maintains its Hold rating for CSL and lifts its target to $152.50 from $133.00 after FY26 revenue of US$15.8bn and underlying NPAT of US$3.0bn modestly beat consensus.
Improving second-half immunoglobulin growth, moderating albumin-price declines in China and a $1.1bn FY27 share buyback offset guidance for flat constant-currency revenue and only 5% guided NPAT growth in FY27.
Behring is expected to return to mid-single-digit growth, while Vifor revenue is forecast to decline -25% because of generic competition.
FY27-FY29 EPS forecasts rise 2.5%, 3.6% and 3.8% respectively.
Target price is $152.50 Current Price is $157.82 Difference: minus $5.32 (current price is over target).
If CSL meets the Ord Minnett target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 637.40 cents and EPS of 1357.94 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 665.11 cents and EPS of 1427.95 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates CSL as Buy (1) -
On further inspection, UBS raises the target price to $181 from $158 and retains a Buy rating. EPS forecasts are lowered by -5% for FY27 and -2% for FY28.
Acknowledging the share price recovery has surprised to the upside, the analyst still sees further upside as the company transitions back to sustainable growth.
First take: it is UBS's first assessment that CSL's FY26 release is in line with revised guidance while FY27 guidance looks like it is slightly better than consensus expectations.
Better than forecast Ig and albumin sales plus strong sales and gross margin for Vifor are underpinning today's positive surprise, commentary highlights.
The broker also notes -US$5.4bn of impairments were booked, which is above expectations, but commentary suggests this will ensure a cleaner FY27 result.
Buy rating with a $158 target.
Target price is $181.00 Current Price is $157.82 Difference: $23.18
If CSL meets the UBS target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $162.32, suggesting downside of -2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 425.90 cents and EPS of 898.48 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 945.7, implying annual growth of N/A. Current consensus DPS estimate is 468.2, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 447.78 cents and EPS of 965.58 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1001.6, implying annual growth of 5.9%. Current consensus DPS estimate is 495.4, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.35
Macquarie rates DRR as Neutral (3) -
Deterra Royalties' FY26 result was in line across all metrics, Macquarie reports. Asset sales reduce net debt to $133m from $271m last year. The dividend was in line on a consistent 75% payout ratio.
Deterra successfully completed the disposal of non-core precious metal assets, reducing the effective cost of acquiring Thacker Pass. Management stated that volatility in commodity and equity markets has caused delays in the acquisition pipeline.
Balance sheet capacity supports medium-term growth optionality, but ongoing MAC concentration and the unresolved CEO appointment limit near-term conviction, Macquarie suggests. Neutral and $4.70 target retained.
Target price is $4.70 Current Price is $4.35 Difference: $0.35
If DRR meets the Macquarie target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $4.58, suggesting upside of 3.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 19.70 cents and EPS of 25.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.8, implying annual growth of N/A. Current consensus DPS estimate is 21.6, implying a prospective dividend yield of 4.9%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 22.40 cents and EPS of 27.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.5, implying annual growth of 6.1%. Current consensus DPS estimate is 22.7, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 15.1. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates DRR as Neutral (3) -
Deterra Royalties' FY26 result reinforced UBS' positive view of its royalty cash flows, with continuing operations revenue rising 6% despite statutory revenue falling -8% to $242m following lower MAC (Mining Area C) capacity payments and portfolio rationalisation.
Strong MAC cash generation and $124m of divestment proceeds supported de-gearing, while the FY26 dividend of 23.2c represented a 75% payout.
The broker sees MAC continuing to underpin earnings and cash flow, with first production from Thacker Pass targeted for late calendar 2027 providing the key medium-term growth catalyst. EPS forecasts are modestly increased following the result.
Target price is lowered to $4.50 from $4.75 on higher US 10-year bond yields. Neutral rated.
Target price is $4.50 Current Price is $4.35 Difference: $0.15
If DRR meets the UBS target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $4.58, suggesting upside of 3.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 22.00 cents and EPS of 29.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.8, implying annual growth of N/A. Current consensus DPS estimate is 21.6, implying a prospective dividend yield of 4.9%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 23.00 cents and EPS of 31.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.5, implying annual growth of 6.1%. Current consensus DPS estimate is 22.7, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 15.1. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $18.23
Citi rates EBO as Buy (1) -
First Take: EBOS Group's FY26 result was in line with Citi's expectations across the P&L, with revenue of $13.5bn and core EBITDA of $614m, up 10% and 5%, respectively.
Healthcare revenue rose 9% to $12.6bn, while Animal Care revenue increased 35% to $907m, with operational execution tracking plans outlined at the recent strategy day.
FY27 core EBITDA guidance of $635m-$655m brackets consensus, with the midpoint implying around 5% growth, while Citi sits at the top end of the range.
The broker believes guidance could prove conservative as the completed distribution centre network drives benefits over the next 2-3 years.
Buy. Target $24.50.
Target price is $24.50 Current Price is $18.23 Difference: $6.27
If EBO meets the Citi target it will return approximately 34% (excluding dividends, fees and charges).
Current consensus price target is $25.14, suggesting upside of 26.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 EPS of 120.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 122.6, implying annual growth of 11.7%. Current consensus DPS estimate is 102.9, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 16.2. |
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 125.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.6, implying annual growth of 4.9%. Current consensus DPS estimate is 100.2, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 15.4. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $13.65
Citi rates EVN as Neutral (3) -
First Take: Evolution Mining delivered a broadly in-line FY26 result, with underlying EBITDA of $3.17bn 1% ahead of Citi and consensus, while underlying NPAT of $1.56bn was -1% below.
Record group cash flow of $1.39bn helped the company finish FY26 with net cash of $19m and fully unhedged, although FY26 dividends of 41c were -7% below expectations.
FY27 gold production guidance of 660-730koz was broadly in line, while AISC guidance of $1,795-1,995/oz was 22% above the analyst's forecast at the midpoint, narrowing to around 7% on comparable copper price assumptions.
Growth capex guidance of $1.08bn was 15% above the broker, reflecting increased development across Cowal, Northparkes and Ernest Henry. Citi sees modest downside risk to FY27 earnings and cash flow forecasts from higher costs and capex.
Neutral rated. Target $13.70.
Target price is $13.70 Current Price is $13.65 Difference: $0.05
If EVN meets the Citi target it will return approximately 0% (excluding dividends, fees and charges).
Current consensus price target is $13.45, suggesting downside of -1.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 44.00 cents and EPS of 76.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 81.0, implying annual growth of 74.2%. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.9. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 55.00 cents and EPS of 92.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 95.4, implying annual growth of 17.8%. Current consensus DPS estimate is 48.5, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates EVN as Neutral (3) -
Initial Impressions: Evolution Mining's FY26 underlying NPAT of $1.56bn came in -1% below Macquarie's expectations, and -2% below consensus, while the 41c FY26 dividend was 2% above the broker but -5% below consensus.
FY27 gold production guidance was broadly in line, although copper production was -5% below expectations and AISC of $1,895/oz at the midpoint was 5% higher, partly reflecting Evolution's lower copper price assumption.
Growth capex guidance of $1.01bn-$1.15bn was around 13% above Macquarie, driven by accelerated mine development at Northparkes, Ernest Henry and Cowal to support future ore delivery.
Macquarie views the FY27 outlook as incrementally weaker due to lower copper production, higher costs and capex.
Neutral. Target $11.50.
Target price is $11.50 Current Price is $13.65 Difference: minus $2.15 (current price is over target).
If EVN meets the Macquarie target it will return approximately minus 16% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $13.45, suggesting downside of -1.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 40.00 cents and EPS of 78.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 81.0, implying annual growth of 74.2%. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 16.9. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 24.00 cents and EPS of 82.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 95.4, implying annual growth of 17.8%. Current consensus DPS estimate is 48.5, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FBU FLETCHER BUILDING LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $3.08
Citi rates FBU as Neutral (3) -
First Take: Citi notes Fletcher Building's FY26 EBIT of NZ$414m was around 5% ahead of consensus and above the company's NZ$400-NZ$403m guidance, with all segments exceeding expectations.
The bulk of the year-on-year EBIT growth came from Wood and Panels, while net debt declined to $637m, or 1.1x, and there was no increase in the Iplex provision.
Management provided only qualitative FY27 guidance, with 1H27 expected to be affected by demand pulled forward into 2H26 ahead of price increases and ongoing macro uncertainty.
The analyst explains that, adjusting for -NZ$52m of land sales in FY26, consensus FY27 EBIT of NZ$396m implies around 9% growth, which is considered achievable given the strong 2H26 exit rate across building products.
Target NZ$3.70. Neutral rated.
Current Price is $3.08. Target price not assessed.
Current consensus price target is $2.76, suggesting downside of -17.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 29.3. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 3.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.2, implying annual growth of 33.3%. Current consensus DPS estimate is 1.1, implying a prospective dividend yield of 0.3%. Current consensus EPS estimate suggests the PER is 22.0. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GOZ GROWTHPOINT PROPERTIES AUSTRALIA
Infra & Property Developers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.12
Citi rates GOZ as Buy (1) -
Citi remains positive on Growthpoint Properties Australia following strong FY26 leasing and improved occupancy, while noting higher finance costs remain a headwind. FY26 funds from operations (FFO) came in near the top of guidance at 23.5cpu.
Record office leasing of 81,022sqm lifted occupancy to 95% and reduced near-term lease expiry risk, the analyst explains.
The broker cuts its FY27 and FY28 DPS forecasts by -4% and -5%, respectively, reflecting lower FFO and higher finance costs.
Growthpoint trades at a -30% discount to net tangible assets (NTA), which Citi considers attractive despite elevated leasing incentives.
Citi retains its Buy rating. Target $2.60.
Target price is $2.60 Current Price is $2.12 Difference: $0.48
If GOZ meets the Citi target it will return approximately 23% (excluding dividends, fees and charges).
Forecast for FY27:
Forecast for FY28:
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.73
Bell Potter rates HCW as Buy (1) -
Bell Potter maintains a Buy rating for HealthCo Healthcare & Wellness REIT with its target price decreased to $0.90 from $0.95 following a FY26 result featuring funds from operations per share of 4.0c and the reinstatement of FY27 distribution guidance.
Management established FY27 guidance for distributions of 6.0c per share alongside a strong cash position of $158m supporting ongoing capital needs.
The analyst highlights that all Healthscope hospitals continue to operate normally with rent paid up to date while the receiver-led process remains ongoing.
The broker's estimates adjust forecasts downward across FY27 to FY29 by -11%-33% to reflect the reinstatement of Unison Healthcare Group earnings and lower cost hedging roll-offs.
The trust trades at a material discount to net tangible assets, offering investors defensive exposure and a high dividend yield, the report concludes.
Target price is $0.90 Current Price is $0.73 Difference: $0.17
If HCW meets the Bell Potter target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $0.83, suggesting upside of 15.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 6.00 cents and EPS of 4.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.2, implying annual growth of N/A. Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 7.9%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 7.20 cents and EPS of 6.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.8, implying annual growth of 11.5%. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 8.9%. Current consensus EPS estimate suggests the PER is 12.4. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates HCW as Underweight (5) -
Morgan Stanley points out HealthCo Healthcare & Wellness REIT has reinitiated its distribution and earnings guidance for FY27 post the FY26 results.
The analyst is somewhat surprised by the decisions while replacement tenants for Healthscope hospitals aren't fully in place yet. The broker also stresses the decision seems at odds with the unlisted fund HCW of which it has a circa 50% stake still not paying a distribution.
This results in a circa -$11m shortfall between FY27 FFO and DPS. There remains material ongoing uncertainty around the resolution to the timing and metrics of a replacement deal, commentary highlights.
Underweight retained. Target rises to 75c from 70c. Industry view: In-Line.
Target price is $0.75 Current Price is $0.73 Difference: $0.02
If HCW meets the Morgan Stanley target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $0.83, suggesting upside of 15.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 6.00 cents and EPS of 4.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.2, implying annual growth of N/A. Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 7.9%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 6.00 cents and EPS of 5.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.8, implying annual growth of 11.5%. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 8.9%. Current consensus EPS estimate suggests the PER is 12.4. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates HCW as Speculative Buy (1) -
HealthCo Healthcare & Wellness REIT missed Morgans's and consensus FY26 FFO by -4% and -6%, respectively, and the -39% fall y/y reflected the suspension of distributions from Unlisted Healthcare Fund.
FY27 distribution guidance is 6c with an updated NTA of $1.25 per share, noted by the analyst. FY26 result is viewed as a good progression to de-risking the REIT.
According to guidance, the broker expects distributions to grow over FY27-FY29 although FFO are expected to decline.
Speculative Buy rated with a lower target of 85c from 95c.
Target price is $0.85 Current Price is $0.73 Difference: $0.12
If HCW meets the Morgans target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $0.83, suggesting upside of 15.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 6.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.2, implying annual growth of N/A. Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 7.9%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 6.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.8, implying annual growth of 11.5%. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 8.9%. Current consensus EPS estimate suggests the PER is 12.4. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.25
UBS rates HSN as Buy (1) -
First Take: Hansen Technologies FY26 EBITDA was in line with UBS despite softer 2H revenue, as stronger cost control lifted the 2H EBITDA margin to 33%, while NPATA beat expectations.
FY27 guidance is materially below expectations, with broadly stable revenue and an underlying EBITDA margin above 26%, versus consensus forecasts for 8% revenue growth and a 31% margin.
The current fiscal year is viewed as an investment and transition year, with AI-related investment expected to support a return to margins above 30% in FY28.
Founder and MD Andrew Hansen will move to Executive Chair in November, with former TechnologyOne COO Stuart McDonald appointed CEO, a transition UBS expects could weigh on sentiment.
Buy. Target $7.20.
Target price is $7.20 Current Price is $4.25 Difference: $2.95
If HSN meets the UBS target it will return approximately 69% (excluding dividends, fees and charges).
Current consensus price target is $6.66, suggesting upside of 93.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 10.00 cents and EPS of 31.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.9, implying annual growth of 31.2%. Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 12.3. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 10.00 cents and EPS of 35.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 32.5, implying annual growth of 16.5%. Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 10.6. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HUB HUB24 LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $79.94
Bell Potter rates HUB as Downgrade to Hold from Buy (3) -
Bell Potter downgrades its recommendation for Hub24 to Hold and reduces its target price to $90.00 from $110.00 following a FY26 result where underlying NPAT beat expectations at $137.3m.
The analyst highlights that underlying EBITDA reached $211.4m alongside a mixed outlook driven by platform funds under administration guidance of $186bn to $200bn and lower early net inflows.
The broker's estimates adjust EBITDA downwards by 4%-5% across forecast periods to reflect softer platform margins and slower cost scaling.
Management reports a strong cash position of $41.0m and declared a fully franked final dividend of 42.0cps.
Commentary points out the stock trades at a high valuation multiple, leaving limited compelling upside relative to near-term net inflow trends.
Target price is $90.00 Current Price is $79.94 Difference: $10.06
If HUB meets the Bell Potter target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $98.43, suggesting upside of 23.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 83.00 cents and EPS of 184.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 188.3, implying annual growth of N/A. Current consensus DPS estimate is 91.5, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 42.2. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 97.00 cents and EPS of 215.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 221.9, implying annual growth of 17.8%. Current consensus DPS estimate is 104.9, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 35.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates HUB as Buy (1) -
Citi remains positive on Hub24's medium-term growth outlook following FY26 results, despite 1Q27 net flows being softer than the consensus estimate.
The broker expects discretionary flows to rebound as uncertainty subsides, forecasting around $18bn in FY27 and $20bn in FY28 net flows.
FY27-FY28 profit forecasts fall around -2%, primarily reflecting slower margin expansion, the broker explains.
It's felt strong adviser advocacy and reinvestment support continued funds under administration (FUM) growth.
Citi lowers its target to $93.50 from $95.00 and retains its Buy rating.
Target price is $93.50 Current Price is $79.94 Difference: $13.56
If HUB meets the Citi target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $98.43, suggesting upside of 23.9% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 188.3, implying annual growth of N/A. Current consensus DPS estimate is 91.5, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 42.2. |
Forecast for FY28:
Current consensus EPS estimate is 221.9, implying annual growth of 17.8%. Current consensus DPS estimate is 104.9, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 35.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates HUB as Overweight (1) -
Hub24's FY26 result was in line with consensus. A trading update suggests first quarter FY27 funds under administration are tracking ahead of consensus, Morgan Stanley notes. An FY28 platform FUA target is also in line with consensus.
The strong start to FY27 underpins the broker's confidence in achieving FY27 and new FY28 targets. Hub24 is number one in net flows for 10 straight quarters, has 9.9% share, but wins 45% of industry flows.
The FY28 FUA target implies an 18% CAGR, reflecting durable share growth and structural industry tailwinds. Morgan Stanley is bullish, but notes the stock traded off on net flows and margin concerns. Overweight and $121 target retained.
Industry view: In-Line.
Target price is $121.00 Current Price is $79.94 Difference: $41.06
If HUB meets the Morgan Stanley target it will return approximately 51% (excluding dividends, fees and charges).
Current consensus price target is $98.43, suggesting upside of 23.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 89.50 cents and EPS of 192.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 188.3, implying annual growth of N/A. Current consensus DPS estimate is 91.5, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 42.2. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 109.00 cents and EPS of 234.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 221.9, implying annual growth of 17.8%. Current consensus DPS estimate is 104.9, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 35.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates HUB as Accumulate (2) -
Ord Minnett maintains Hub24 on Accumulate and reduces its target to $93.00 from $95.00 following an in-line FY26 result.
EBITDA increased 30% to $211.4m and the margin expanded 2.3 percentage points to 42.3%, although net inflows slowed to around $2bn during the first six weeks of FY27 from a FY26 quarterly average of $4.7bn.
The broker considers the slowdown temporary and sees support from Hub24's FY28 funds-under-administration target of $186bn–$200bn, representing 38% two-year growth at the midpoint.
FY27–FY28 EBITDA forecasts fall -1–4%. Commentary states prolonged weakness in discretionary flows and investor sentiment is the primary risk.
Target price is $93.00 Current Price is $79.94 Difference: $13.06
If HUB meets the Ord Minnett target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $98.43, suggesting upside of 23.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 89.60 cents and EPS of 184.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 188.3, implying annual growth of N/A. Current consensus DPS estimate is 91.5, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 42.2. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 107.50 cents and EPS of 214.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 221.9, implying annual growth of 17.8%. Current consensus DPS estimate is 104.9, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 35.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates HUB as Neutral (3) -
Persistent weakness in non-super flows overshadowed HUB24's FY26 result, with UBS noting the implied 1Q27 flow run-rate of around $4bn per quarter represents a -22% slowdown and raises the risk of a more prolonged moderation.
FY26 UNPAT of $137m was 1%-3% ahead of expectations and consensus due to a lower tax rate, although Platform earnings missed by -5% as fee margin compression weighed on revenue and the 2H26 EBITDA margin.
Platform FUA reached $144.1bn by August 13, including around $2bn of net flows since June, reinforcing the broker's cautious near-term flow outlook.
FY27-FY29 EPS forecasts are tweaked by up 0.5%, -1% and -3%, respectively, reflecting weaker flows and fee margins partly offset by lower cost growth.
Target slips to $83.50 from $86 and the analyst sees more attractive entry points potentially emerging as flow and margin expectations reset. Neutral rated.
Target price is $83.50 Current Price is $79.94 Difference: $3.56
If HUB meets the UBS target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $98.43, suggesting upside of 23.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 91.00 cents and EPS of 190.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 188.3, implying annual growth of N/A. Current consensus DPS estimate is 91.5, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 42.2. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 106.00 cents and EPS of 223.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 221.9, implying annual growth of 17.8%. Current consensus DPS estimate is 104.9, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 35.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.75
Ord Minnett rates IMD as Upgrade to Buy from Hold (1) -
Ord Minnett upgrades Imdex to Buy from Hold and sets a $4.50 target following record FY26 revenue and earnings.
Revenue increased 21% to $520m and normalised EBITDA rose 29% to $163m, respectively 1% and 2% above consensus, as organic growth reached 17% and platform revenue expanded to 47% of group sales.
Market-share gains, five recent acquisitions and supportive exploration spending underpin a forecast three-year EPS compound annual growth rate of 22%, although higher depreciation, finance costs and research expenditure temper the outlook.
EPS forecasts rise 1.8% in FY27 and 7.1% in FY29 but fall -2.9% in FY28.
Target price is $4.50 Current Price is $3.75 Difference: $0.75
If IMD meets the Ord Minnett target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $4.57, suggesting upside of 22.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 3.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.7, implying annual growth of -11.7%. Current consensus DPS estimate is 3.8, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 27.2. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 4.00 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.0, implying annual growth of 16.8%. Current consensus DPS estimate is 4.6, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 23.3. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IRE IRESS LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $6.40
Ord Minnett rates IRE as Buy (1) -
Ord Minnett points out revenue headwinds overshadowed otherwise solid margin improvement for Iress in 1H26, with constant currency revenue growth of nearly 3%, below consensus, while UPAT rose 18% y/y but also missed expectations.
Lower non-recurring revenue and FX headwinds prompted management to cut FY26 revenue guidance to $499-$505m from $520-$528m, although cost efficiencies limited the reduction in UPAT guidance to $82-$86m from $84-$90m.
The analyst notes delayed client wins could shift project commencements into FY27 rather than represent lost opportunities, while the interim dividend increased 27% to 14c.
EPS forecasts fall just -0.2%, -1.6% and -1.3% across FY26-FY28 as cost reductions and lower depreciation and amortisation largely offset weaker revenue.
Buy retained but the target slips to $11.30 from $11.60, citing valuation upside and potential benefits from further efficiencies, UK project wins and a move to net cash.
Target price is $11.30 Current Price is $6.40 Difference: $4.9
If IRE meets the Ord Minnett target it will return approximately 77% (excluding dividends, fees and charges).
Current consensus price target is $9.56, suggesting upside of 56.9% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Ord Minnett forecasts a full year FY26 dividend of 31.00 cents and EPS of 43.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 43.2, implying annual growth of 1.3%. Current consensus DPS estimate is 29.3, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.1. |
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 35.00 cents and EPS of 49.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 47.2, implying annual growth of 9.3%. Current consensus DPS estimate is 32.7, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JDO JUDO CAPITAL HOLDINGS LIMITED
Business & Consumer Credit
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.07
Citi rates JDO as Buy (1) -
Judo Capital's FY26 PBT of $168m was around 2% ahead of Citi and consensus, while FY27 PBT guidance of $210m–$220m was maintained and is broadly in line with consensus.
Management is believed to have provided greater clarity around loan book composition and concentration risk following the large provision charges in 2H26, although rebuilding investor trust around credit risk will take time, Citi suggests.
The broker sees positive developments in capital solutions and at-call products supporting funding and NIM management, adding credibility to guidance for broadly stable NIM.
EPS forecasts decline by -9%, mainly due to increased dilution from capital notes and options.
Citi retains Buy, noting the shares trade at around 7x against forecast earnings growth of around 25%–30%.
Target price is $1.50 Current Price is $1.07 Difference: $0.43
If JDO meets the Citi target it will return approximately 40% (excluding dividends, fees and charges).
Current consensus price target is $1.42, suggesting upside of 40.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 8.1. |
Forecast for FY28:
Citi forecasts a full year FY28 dividend of 0.00 cents and EPS of 16.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.7, implying annual growth of 33.6%. Current consensus DPS estimate is 0.4, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 6.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates JDO as Outperform (1) -
Judo Capital's FY26 result provided limited new information given recent updates, Macquarie notes, and FY27 guidance was broadly in line with consensus.
However, management on the earnings call shared progress on the impaired loans that drove the downgrade in June, flagging that arrears may be cleared.
Credit quality remains a near-term concern, Macquarie warns. However, underlying revenue trends remain solid. After the recent downgrade, consensus expectations have been re-based.
Trading at only 0.6x price-to-book, the broker thinks the risk-reward is favourable. Outperform retained, target rises to $1.65 from $1.55.
Target price is $1.65 Current Price is $1.07 Difference: $0.58
If JDO meets the Macquarie target it will return approximately 54% (excluding dividends, fees and charges).
Current consensus price target is $1.42, suggesting upside of 40.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 13.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 8.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 2.00 cents and EPS of 17.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.7, implying annual growth of 33.6%. Current consensus DPS estimate is 0.4, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 6.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates JDO as Overweight (1) -
Judo Capital's FY26 profit, cost of risk and gross loans were in line with the guidance provided in June. There's no change to FY27 profit guidance of $210-$220m, which implies 25%-31% year on year growth. Morgan Stanley notes.
The broker forecasts circa 18% pre-provision profit growth in FY27 but believes loan losses will be the key earnings 'swing' factor. In Morgan Stanley's view, the amount of large single-name exposures means there is potential for higher loan loss volatility.
There are no major surprises in the new FY27 guidance for loan growth, margins, capital ratio and cost of risk. Target rises to $130 from $125, Overweight retained. Industry view: Cautious.
Target price is $1.30 Current Price is $1.07 Difference: $0.23
If JDO meets the Morgan Stanley target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $1.42, suggesting upside of 40.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 8.1. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 0.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.7, implying annual growth of 33.6%. Current consensus DPS estimate is 0.4, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 6.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates JDO as Buy (1) -
Judo Capital's 2H26 profit before tax rose 18% y/y and came in at the upper end of revised guidance, Morgans notes. The results beat consensus by around 6% while post-tax earnings missed by -5% due to a large tax expense from a weak share price.
The analyst expects FY27 loan growth at 12% which aligns with management's "disciplined above system growth". FY27 NIM guidance is "broadly stable on FY27", and the analyst forecasts NIM of 315bps.
FY27 PBT guidance infers 25%-31% growth. EPS forecasts are trimmed by -2% to -6% for FY27-FY29 on costs and impairments.
The CET1 ratio was 12.4% at FY26 end, above the 11%-12% range.
No change in Buy rating. Target slips to $1.42 from $1.47.
Target price is $1.42 Current Price is $1.07 Difference: $0.35
If JDO meets the Morgans target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $1.42, suggesting upside of 40.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 8.1. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.7, implying annual growth of 33.6%. Current consensus DPS estimate is 0.4, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 6.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates JDO as Neutral (3) -
Credit quality remains the key hurdle for Judo Capital despite strong underlying FY26 performance, with 18% lending growth, NIM of 3.13% and the cost-to-income ratio improving to 45.3%, UBS explains.
FY27 PBT guidance of $210-$220m implies 25%-31% growth and around 8% ROE, but the expected credit loss ratio is forecast to remain around FY26's elevated 88bps, limiting confidence in a path towards management's low-to-mid teens ROE target.
The broker remains particularly cautious around customer concentration, with 19 customer groups carrying exposures above $50m, including six above $100m, which could continue to drive provisioning volatility.
Neutral rated. Target $1.05.
Target price is $1.05 Current Price is $1.07 Difference: minus $0.02 (current price is over target).
If JDO meets the UBS target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $1.42, suggesting upside of 40.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 8.1. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 0.00 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.7, implying annual growth of 33.6%. Current consensus DPS estimate is 0.4, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 6.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.80
Citi rates LLC as Downgrade to Neutral from Buy (3) -
In the wake of FY26 results for Lendlease Group, Citi lowers its target by -$1.40 to $3.10 and downgrades to Neutral from Buy following disappointing FY27 earnings guidance and continued elevated gearing.
FY27 EPS guidance of 37c–41c is around -30% below the broker's prior forecast, reflecting higher debt costs and weaker investment income.
The analysts see further downside risk from Melbourne residential conditions, project delays and potential fund redemptions.
First take: On first glance, Citi notes Lendlease Group's FY26 results present a mixed picture, with core IDC earnings landing near the top of guidance, while the total earnings loss of -82.1c was wider than expected, dragged down by capital recycling losses.
While the construction backlog remains robust and FY27 development earnings are supported by pre-sales, funds under management fell -10% on redemptions lowering investment earnings into FY27.
Gearing has escalated to 37.7% (excluding hybrid benefits), up significantly from 26.6% last year. Citi expects a weak response to the result.
Target price is $3.10 Current Price is $2.80 Difference: $0.3
If LLC meets the Citi target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $3.48, suggesting upside of 26.2% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 22.9, implying annual growth of N/A. Current consensus DPS estimate is 13.0, implying a prospective dividend yield of 4.7%. Current consensus EPS estimate suggests the PER is 12.1. |
Forecast for FY28:
Current consensus EPS estimate is 35.2, implying annual growth of 53.7%. Current consensus DPS estimate is 14.4, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 7.8. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.74
Citi rates MGR as Buy (1) -
In an early assessment, Citi views today's FY26 result by Mirvac Group positively, with in-line EPS of 12.9c, better-than-feared FY27 guidance and a new $200m buyback.
FY27 EPS guidance of 13.2-13.4cpu implies to the broker around 3% growth, while 63% of residential earnings are already secured through pre-sales, the analyst explains.
Gearing declined materially to 24.1%, supporting the buyback, while net tangible assets (NTA) rose 3.1% to $2.33 per security, the analysts highlight.
Mirvac's -25% discount to NTA is noted. Attention is now expected to shift towards execution and development pipeline delivery.
Buy rating. Target $2.00.
Target price is $2.00 Current Price is $1.74 Difference: $0.26
If MGR meets the Citi target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $2.01, suggesting upside of 8.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.0, implying annual growth of 655.8%. Current consensus DPS estimate is 9.5, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 14.2. |
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.2, implying annual growth of 1.5%. Current consensus DPS estimate is 9.8, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 14.0. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MGR as Neutral (3) -
First Take: UBS notes Mirvac Group's FY26 result was broadly in line, with operating EPS of 12.9c matching expectations, and FY27 guidance for 13.2c-13.4c also as anticipated.
Residential development was a key positive, with FY27 settlement guidance of 2,800-3,100 lots well above the broker's forecast and consensus.
Commentary states it is difficult to reconcile with modest EPS growth and implies weaker expectations elsewhere in development.
A $200m on-market buyback is considered a positive, while 4Q26 residential sales softened -11% q/q and -15% on pcp.
Neutral. Target $1.97.
Target price is $1.97 Current Price is $1.74 Difference: $0.23
If MGR meets the UBS target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $2.01, suggesting upside of 8.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 9.50 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.0, implying annual growth of 655.8%. Current consensus DPS estimate is 9.5, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 14.2. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 10.00 cents and EPS of 13.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.2, implying annual growth of 1.5%. Current consensus DPS estimate is 9.8, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 14.0. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $20.84
Citi rates MP1 as Buy (1) -
Citi remains positive on Megaport, with July hiring data indicating strong employee growth despite signs recruitment activity is slowing.
LinkedIn headcount rose 41% year-on-year, including 22 additions in July, likely supported by hiring for Latitude, the analyst explains.
The broker sees no concerns around Latitude demand or revenue growth.
Market uncertainty around Latitude's EBITDA margins is noted. These were previously guided to the mid-40% range, but the analyst forecasts 63% in FY27 following recent contract wins.
Citi retains its Buy rating and target of $22.10.
Target price is $22.10 Current Price is $20.84 Difference: $1.26
If MP1 meets the Citi target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $20.85, suggesting upside of 2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -1.8, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.2, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 112.2. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PME PRO MEDICUS LIMITED
Medical Equipment & Devices
More Research Tools In Stock Analysis - click HERE
Overnight Price: $196.75
Bell Potter rates PME as Buy (1) -
Bell Potter maintains a Buy rating for Pro Medicus with a $226.00 target price following a solid FY26 result featuring 23% revenue growth and 26% EBIT growth.
The analyst highlights that EBIT margins expanded by 190bps to 75%, driven by incredible operating leverage and strong contract execution.
The broker's estimates adjust FY27 earnings per share upward by 8% following revenue adjustments and expectations of continued strong installation activity.
Management successfully retained all six expiring contracts during the year, while major upcoming renewals over the next 12 months present significant potential price catalysts.
Commentary states the balance sheet remains gold-plated with cash of $216m supporting ongoing dividend growth.
Target price is $226.00 Current Price is $196.75 Difference: $29.25
If PME meets the Bell Potter target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $225.00, suggesting upside of 13.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 99.10 cents and EPS of 198.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 196.0, implying annual growth of N/A. Current consensus DPS estimate is 90.3, implying a prospective dividend yield of 0.5%. Current consensus EPS estimate suggests the PER is 100.9. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 110.40 cents and EPS of 221.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 255.4, implying annual growth of 30.3%. Current consensus DPS estimate is 116.1, implying a prospective dividend yield of 0.6%. Current consensus EPS estimate suggests the PER is 77.5. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates PME as Accumulate (2) -
Morgans believes Pro Medicus's FY26 result shows the company is executing at an even higher level than the market was ascribing to the stock.
In FY26, EBIT margin was 74.9% and constant currency EBIT growth came in at 30.6%, both beating expectations.
FY27 is positioning to be another "stand out year" the analyst states with four Trinity and 15 other implementations already in the bag. Forward contracted revenue rose 41.3% to $1.34bn and the five-year CAGR stands at 29%.
The analyst views the FY27 revenue expectation of around $335m as less speculative than a few months ago.
The stock remains Accumulate rated with a $230 target and is viewed by the broker as one of the highest-quality businesses on the ASX.
Target price is $230.00 Current Price is $196.75 Difference: $33.25
If PME meets the Morgans target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $225.00, suggesting upside of 13.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 97.00 cents and EPS of 250.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 196.0, implying annual growth of N/A. Current consensus DPS estimate is 90.3, implying a prospective dividend yield of 0.5%. Current consensus EPS estimate suggests the PER is 100.9. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 120.00 cents and EPS of 309.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 255.4, implying annual growth of 30.3%. Current consensus DPS estimate is 116.1, implying a prospective dividend yield of 0.6%. Current consensus EPS estimate suggests the PER is 77.5. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates PME as Buy (1) -
Ord Minnett points out FY26 results from Pro Medicus were a slight beat, with revenue better than consensus and underlying NPAT also a beat on market expectations.
Currency headwinds remained, but on a constant currency basis revenue rose 28% and NPAT up 33%. Post the final DPS of 37c, the total FY26 DPS at 69c is up 26%.
The broker points out shares have been heavily shorted (some 8% of the free float), which resulted in an outsized share price reaction to the results.
With only 11% market share of the radiology network, Ord Minnett believes there is significant scope for gains. Management hopes to target the "next 10%" in a faster time frame versus the "first 10%".
Target price rises to $230 from $210 with a Buy rating. The analyst highlights a robust pipeline of growth opportunities for the company and FY27 revenues already seem to be secured via existing contracts.
Target price is $230.00 Current Price is $196.75 Difference: $33.25
If PME meets the Ord Minnett target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $225.00, suggesting upside of 13.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 91.00 cents and EPS of 182.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 196.0, implying annual growth of N/A. Current consensus DPS estimate is 90.3, implying a prospective dividend yield of 0.5%. Current consensus EPS estimate suggests the PER is 100.9. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 118.00 cents and EPS of 236.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 255.4, implying annual growth of 30.3%. Current consensus DPS estimate is 116.1, implying a prospective dividend yield of 0.6%. Current consensus EPS estimate suggests the PER is 77.5. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $7.88
Macquarie rates PXA as Outperform (1) -
Pexa Group has released its submission in response to the IPART draft report, alongside three independent expert reports. Capturing eight initial asset base (IAB) estimates using varying approaches suggests an IAB 3.8x above IPART's draft recommendation, Macquarie notes.
Pexa's submission suggests draft IAB is too low, the broker reports, and the company has pushed back on review methodology, questioning IPART's calculations.
Macquarie reiterates Outperform, expecting some or all of the -20% price cut will be walked back by IPART and/or offset by alternate revenue streams. Target unchanged at $15.15.
Target price is $15.15 Current Price is $7.88 Difference: $7.27
If PXA meets the Macquarie target it will return approximately 92% (excluding dividends, fees and charges).
Current consensus price target is $12.16, suggesting upside of 53.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 0.00 cents and EPS of 13.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.9, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 28.4. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 14.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.7, implying annual growth of 13.6%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 25.0. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates PXA as Neutral (3) -
A sharp slowdown in property transfer volumes has prompted UBS to materially cut PEXA's FY27 earnings outlook, with July volumes around -8% below the 2H26 monthly average and -15% to -22% below previous expectations.
FY26 Australian Exchange transactions of 4.19m were slightly ahead, but the broker now forecasts FY27 volume growth of -10% from -3% previously, driving EPS changes of up 3% for FY26 and -31% for FY27.
Separately, PEXA is challenging IPART's draft ELNO fee methodology, with independent analysis supporting an Initial Asset Base of $580m-$1.3bn versus IPART's $368m.
UBS believes the independent valuations could provide scope for concessions from IPART despite largely reinforcing PEXA's existing position. Neutral rated. Target falls to $9 from $9.80.
Target price is $9.00 Current Price is $7.88 Difference: $1.12
If PXA meets the UBS target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $12.16, suggesting upside of 53.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 28.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.9, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 28.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 29.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.7, implying annual growth of 13.6%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 25.0. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Bell Potter rates RGN as Buy (1) -
Bell Potter maintains a Buy rating for Region Group with its target price decreased to $2.55 from $2.60 following the REIT reporting FY26 funds from operations per share of 16.0c, in line with guidance and consensus.
Management established FY27 guidance for funds from operations per share of 16.5c alongside distributions per share of 14.5c.
The analyst highlights that comprehensive rate hedging and robust non-discretionary retail exposure insulate earnings against near-term macro pressures.
The broker adjusts FY27 to FY29 funds from operations per share estimates by 0% to -2% to reflect an updated Bank Bill Swap rate outlook in addition to portfolio transactions.
Commentary states the stock trades at an attractive forward price-to-earnings discount compared to the passive real estate investment trust sector average, offering a defensive yield above 6%.
Target price is $2.55 Current Price is $2.31 Difference: $0.24
If RGN meets the Bell Potter target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $2.44, suggesting upside of 7.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 14.50 cents and EPS of 16.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.4, implying annual growth of N/A. Current consensus DPS estimate is 14.6, implying a prospective dividend yield of 6.5%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 14.90 cents and EPS of 16.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.0, implying annual growth of 3.7%. Current consensus DPS estimate is 15.0, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates RGN as Buy (1) -
Citi views Region Group's FY26 result as "solid", with comparable net operating income growth the standout and FY27 guidance slightly below the consensus estimate.
Comparable net operating income (NOI) rose 3.3%, as 3% revenue growth exceeded 2.5% expense growth, despite inflationary pressures and gross leases, the analysts explain.
The broker considers 3% FY27 funds from operations (FFO) growth guidance conservative, with similar funds management activity to FY26 potentially lifting growth closer to 4%.
Region Group trades at around an -11% discount to net tangible assets (NTA), Citi highlights, with asset recycling and enhancement projects offering re-rating potential.
Buy rating. Target $2.60.
Target price is $2.60 Current Price is $2.31 Difference: $0.29
If RGN meets the Citi target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $2.44, suggesting upside of 7.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 14.50 cents and EPS of 16.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.4, implying annual growth of N/A. Current consensus DPS estimate is 14.6, implying a prospective dividend yield of 6.5%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
Current consensus EPS estimate is 17.0, implying annual growth of 3.7%. Current consensus DPS estimate is 15.0, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates RGN as Underweight (5) -
Region Group delivered FY26 funds from operations of 16cps, in line with guidance. Management has guided to FY27 FFO of 16.5cps, a touch below the 16.6cps Morgan Stanley was expecting.
Portfolio metrics were fine, the broker suggests, with total Moving Annual Turnover (MAT) growing 3.3% during the year and accelerating in the second half. Supermarket sales growth was strong (4.1% MAT), but specialty less so (2.5% MAT).
Region's hedge rate of 3% is among the lowest in Morgan Stanley's coverage universe. In theory, this means that the cost of debt tailwinds that its peers could enjoy in the event of an RBA rate cut cycle won't eventuate at Region.
But until then, the company has one of the lowest costs of capital among A-REITs at just 4.5%. The broker nonetheless retains Underweight and a $2.30 target. Industry View: In-Line.
Target price is $2.30 Current Price is $2.31 Difference: minus $0.01 (current price is over target).
If RGN meets the Morgan Stanley target it will return approximately minus 0% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.44, suggesting upside of 7.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 14.50 cents and EPS of 16.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.4, implying annual growth of N/A. Current consensus DPS estimate is 14.6, implying a prospective dividend yield of 6.5%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 15.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.0, implying annual growth of 3.7%. Current consensus DPS estimate is 15.0, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates RGN as Neutral (3) -
Region Group delivered FY26 FFO of 16c per share in line with UBS, while FY27 guidance for 3% FFO and AFFO per share growth was slightly below consensus.
The guidance is viewed as a floor given no contribution from external growth initiatives and 83% interest rate hedging.
New management has prioritised internal growth through centre enhancements, with $55m of projects completed or underway targeting yields on cost above 7%, followed by capital recycling and then buybacks.
UBS makes minor FFO per share forecast changes for FY27-FY29, with rising debt costs expected to constrain growth in later years. The broker retains Neutral and its $2.45 target.
Target price is $2.45 Current Price is $2.31 Difference: $0.14
If RGN meets the UBS target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $2.44, suggesting upside of 7.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 15.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.4, implying annual growth of N/A. Current consensus DPS estimate is 14.6, implying a prospective dividend yield of 6.5%. Current consensus EPS estimate suggests the PER is 13.8. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 15.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.0, implying annual growth of 3.7%. Current consensus DPS estimate is 15.0, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
RWC RELIANCE WORLDWIDE CORP. LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.50
Citi rates RWC as Neutral (3) -
Citi remains Neutral-rated on Reliance Worldwide following an in-line FY26 result, with Brookfield's non-binding $4.75 per share bid now the key focus.
The broker believes the shares could exceed the offer price over time as the cycle improves and one-off costs unwind.
Limited downside is expected if the bid fails, with the analyst noting Brookfield's lowest offer was $4.15 and Reliance has received multiple other approaches.
Citi raises its target to $4.75 from $3.90.
Target price is $4.75 Current Price is $4.50 Difference: $0.25
If RWC meets the Citi target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $4.38, suggesting downside of -0.0% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 26.2, implying annual growth of N/A. Current consensus DPS estimate is 5.1, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Current consensus EPS estimate is 29.1, implying annual growth of 11.1%. Current consensus DPS estimate is 5.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 15.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates RWC as Outperform (1) -
Macquarie does not report how Reliance Worldwide's FY26 revenue and earnings stood up against consensus, but notes stronger Americas earnings offsetting weaker Asia-Pacific and Europe, Middle East & Africa performance.
Americas sales increased 8.3% in 2H26, while pricing, sourcing changes and cost-outs are progressively mitigating tariffs and broader inflation.
The Brookfield process is now the key near-term driver, Macquarie notes, with the $4.75/share proposal subject to confirmatory due diligence and negotiation of a binding agreement.
If the transaction does not proceed, improving Americas volume, tariff mitigation and end-market recovery will be key. Target falls to $4.75 from $4.90 to match the bid price. Outperform retained.
Target price is $4.75 Current Price is $4.50 Difference: $0.25
If RWC meets the Macquarie target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $4.38, suggesting downside of -0.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 24.07 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 26.2, implying annual growth of N/A. Current consensus DPS estimate is 5.1, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 0.00 cents and EPS of 28.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.1, implying annual growth of 11.1%. Current consensus DPS estimate is 5.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 15.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates RWC as Equal-weight (3) -
Reliance Worldwide posted an in-line FY26 result but FY27 guidance looks softer on margins despite mid-to-high single-digit sales growth, Morgan Stanley notes.
Americas earnings beat consensus despite revenue missing. Second half margin recovery supports the view that tariff and pricing actions are working. Asia Pacific beat but earnings missed, highlighting a materially weaker margin outcome, Morgan Stanley points out.
FY27 sales guidance looks supportive, the broker notes, but flat group margins imply copper and other input inflation is absorbing much of the cost-out and operating leverage.
The broker retains Equal-weight with a $3.50 target, noting Brookfield has offered $4.75 (non-binding). Industry view: In Line.
Target price is $3.50 Current Price is $4.50 Difference: minus $1 (current price is over target).
If RWC meets the Morgan Stanley target it will return approximately minus 22% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $4.38, suggesting downside of -0.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 27.71 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 26.2, implying annual growth of N/A. Current consensus DPS estimate is 5.1, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 30.63 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.1, implying annual growth of 11.1%. Current consensus DPS estimate is 5.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 15.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates RWC as Hold (3) -
Reliance Worldwide's FY26 result was largely as expected, albeit Morgans points out the margin outlook was slightly weaker than anticipated.
Earnings were surpassed by the Brookfield Capital Partners bid to acquire 100% of the company at $4.75 per share, which was a 31.6% premium to the last closing price of $3.61.
The analyst lifts the target to $4.62 from $3.60 with an unchanged Hold rating. FY27-FY29 EBITDA forecasts are lowered by -5%.
Management has agreed to a four-week exclusivity period where both parties will work towards a scheme implementation deed.
Target price is $4.62 Current Price is $4.50 Difference: $0.12
If RWC meets the Morgans target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $4.38, suggesting downside of -0.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 7.00 cents and EPS of 27.71 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 26.2, implying annual growth of N/A. Current consensus DPS estimate is 5.1, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 8.31 cents and EPS of 32.09 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.1, implying annual growth of 11.1%. Current consensus DPS estimate is 5.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 15.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates RWC as Hold (3) -
Reliance Worldwide announced a -15% fall in FY26 adjusted NPAT due to lower volumes, higher commodity costs and US tariffs.
But Brookfield announced a bid to acquire 100% of the company for $4.75 per share. Ord Minnett believes that given how challenging the macro backdrop is, the bid looks attractive and the Board has granted due diligence.
FY27 sales guidance is for growth in the mid-to-high single digits due to new products and price rises.
The end market conditions are not anticipated to improve.
Hold rated with a higher target of $4.75 from $4.
Target price is $4.75 Current Price is $4.50 Difference: $0.25
If RWC meets the Ord Minnett target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $4.38, suggesting downside of -0.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 6.56 cents and EPS of 26.25 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 26.2, implying annual growth of N/A. Current consensus DPS estimate is 5.1, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 7.29 cents and EPS of 29.03 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.1, implying annual growth of 11.1%. Current consensus DPS estimate is 5.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 15.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $22.97
Macquarie rates SGM as Outperform (1) -
Sims reported FY26 revenue up 7%. Macquarie notes underlying earnings increased 168%, driven by Sims Lifecycle Services (SLS) and strong North American metals earnings.
SLS earnings increased 5x but guided below consensus for 1HFY27, while SA Recycling (SAR) materially outperformed expectations on non-ferrous dynamics, the broker notes.
SLS and SAR have strengthened Sims' earnings base, while firm non-ferrous markets and supportive US steel fundamentals should continue to benefit the metals businesses.
Near-term SLS timing and weaker A&NZ ferrous conditions remain the key issues in the broker's view.
Target rises to $35.10 from $34.40, Outperform retained.
Target price is $35.10 Current Price is $22.97 Difference: $12.13
If SGM meets the Macquarie target it will return approximately 53% (excluding dividends, fees and charges).
Current consensus price target is $30.03, suggesting upside of 32.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 62.00 cents and EPS of 205.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 182.0, implying annual growth of N/A. Current consensus DPS estimate is 60.5, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 54.00 cents and EPS of 177.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 165.0, implying annual growth of -9.3%. Current consensus DPS estimate is 54.0, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 13.7. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates SGM as Equal-weight (3) -
Sims's FY26 earnings were 10% above consensus and 25% above the guidance midpoint. Sims Lifecycle Services (SLS) earnings were in line but 1H27 guidance is -33% below 2H26 and -32% below consensus on more variable data centre decommissioning timing.
SA Recycling posted a standout result, Morgan Stanley suggests, with earnings 43% above consensus and up 96% year on year, driving most of the Group earnings beat.
In metals, Americas earnings were -12% below consensus despite 70% growth, while A&NZ was broadly in line amid weak ferrous markets.
The headline FY26 beat is encouraging, Morgan Stanley suggests, but the softer SLS start to FY27 leaves more work for 2H27 to meet current expectations. Equal-weight and $26 target retained. Industry view: In Line.
Target price is $26.00 Current Price is $22.97 Difference: $3.03
If SGM meets the Morgan Stanley target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $30.03, suggesting upside of 32.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 159.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 182.0, implying annual growth of N/A. Current consensus DPS estimate is 60.5, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 153.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 165.0, implying annual growth of -9.3%. Current consensus DPS estimate is 54.0, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 13.7. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.05
Citi rates SGP as Buy (1) -
On further inspection, Citi stresses the data centre opportunity as extending beyond FY27, with seven sites capable of generating profits from land transfers, development fees and post-completion gains.
Funding requirements may be lower than feared as some sites could be sold as powered land.
MPC margins are expected to decline from FY26's 21.2% as higher-margin projects roll off, although more than 3,800 pre-sales provide solid volume visibility and July's sales slowdown stabilised in August.
Capital is being redirected from office into data centres, logistics and land lease, while the cost of debt is expected to rise to 5.9% in FY27 from 5.3%. Buy rated. Target $5.10.
In an early review, Citi remains positive on Stockland following today's strong FY26 result and FY27 guidance 6% above consensus, supported by data centre development profits.
FY26 funds from operations (FFO) of 36.9cpu was 1% above consensus, while residential settlements of 8,902 also exceeded expectations.
FY27 FFO guidance of 38cpu-39cpu implies to the analyst around 4% growth, with data centre profits the key source of the guidance beat.
Net tangible assets (NTA) rose 4% to $4.39 per security, leaving Stockland trading at an -8% net tangible asset (NTA) discount, Citi highlights.
Buy rating. Target $5.10.
Target price is $5.10 Current Price is $4.05 Difference: $1.05
If SGP meets the Citi target it will return approximately 26% (excluding dividends, fees and charges).
Current consensus price target is $4.84, suggesting upside of 6.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 EPS of 37.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.6, implying annual growth of 5.7%. Current consensus DPS estimate is 25.1, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 37.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.0, implying annual growth of -1.6%. Current consensus DPS estimate is 24.5, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SGP as Neutral (3) -
First Take: Stockland's FY26 result beat expectations, with residential settlements well ahead of UBS and consensus, while FY27 FFO guidance of 38.0-39.0cps is around 10% above expectations and 6% above consensus at the midpoint.
The analyst suggests the guidance beat likely includes a one-off contribution from land vended into the EdgeConnex partnership, while land lease settlement guidance was also stronger than expected.
The broker views the broader contribution across business lines positively, although FY27 MPC settlement guidance was softer than hoped.
Neutral. Target $4.35.
Target price is $4.35 Current Price is $4.05 Difference: $0.3
If SGP meets the UBS target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $4.84, suggesting upside of 6.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 25.00 cents and EPS of 36.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.6, implying annual growth of 5.7%. Current consensus DPS estimate is 25.1, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 25.00 cents and EPS of 35.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.0, implying annual growth of -1.6%. Current consensus DPS estimate is 24.5, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $8.57
Morgans rates SKS as Accumulate (2) -
Having recently pre-reported its FY26 metrics, Morgans points out the actual FY26 results were largely in line with expectations and showed PBT growth of 89% y/y.
FY27 guidance for PBT growth is around 53% which is well supported by the current work in hand, the analyst states. The tender pipeline has grown to $1.69bn.
The broker believes the company is well positioned to see further contract wins towards the end of 2026.
Earnings forecasts are largely unchanged but the target rises to $9.80 from $9.40. Accumulate rating retained.
Target price is $9.80 Current Price is $8.57 Difference: $1.23
If SKS meets the Morgans target it will return approximately 14% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 11.50 cents and EPS of 36.00 cents. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 13.60 cents and EPS of 43.00 cents. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates SKY as Speculative Buy (1) -
Sky Metals' Tallebung PFS outlines a 7.3-year tin-tungsten-silver project with pre-tax NPV8 of $438m and IRR of 69%, based on pre-production capex of $138.8m.
Morgans highlights the PFS mine plan uses only around 66% of the current 32.7Mt resource and around 42% of contained tin, providing significant potential for resource conversion and mine-life extensions ahead of the DFS targeted for 1Q27.
The broker also sees upside from improved tungsten and silver recoveries and payability, with the two metals accounting for around 41% of modelled life-of-mine revenue.
Forecasts are updated for the PFS, July 2026 resource and revised commodity prices, with Morgans modelling an initial mine life of around 8.4 years.
Following an analyst change, the broker retains Speculative Buy and raises its target to $0.40 from $0.35.
Target price is $0.40 Current Price is $0.21 Difference: $0.195
If SKY meets the Morgans target it will return approximately 95% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.30 cents. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of minus 6.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.12
Citi rates SLC as Buy (1) -
First Take: Superloop's FY26 underlying EBITDA rose 33% and came in 2% ahead of Citi and consensus, as a higher gross margin offset slightly weaker revenue.
NPATA of $42m was 16% ahead, mainly due to a lower tax rate, while operating cash flow of $117m beat the analysts' expectations by 16% and consumer net additions remained strong.
The broker highlights operating leverage, with the EBITDA margin expanding around 150bps to 18%, while Smart Communities contracted lots increased to 190k.
Offsetting this, consumer gross margin softened, wholesale subscriber additions were below expectations and capex of $38m exceeded guidance. Citi notes FY29 targets were reiterated, with FY27 guidance due at the AGM.
Buy. Target $3.75.
Target price is $3.75 Current Price is $3.12 Difference: $0.63
If SLC meets the Citi target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $3.70, suggesting upside of 11.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.9, implying annual growth of 2775.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 48.0. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.4, implying annual growth of 50.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 31.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates SLC as Neutral (3) -
First Impressions: Superloop's reported FY26 underlying EBITDA of $123m met Macquarie's expectations and came in 2% ahead of consensus, while NPAT of $17.5m was 13% ahead of the broker.
Revenue rose 21% y/y with Consumer net additions 16% ahead of Macquarie, although Wholesale additions were -3% below.
The underlying EBITDA margin expanded 160bps to 18.5%, while free cash flow increased to $84.4m and net debt/EBITDA of 1.3x was better than expected.
Capex of $37.9m was above guidance, while Smart Communities contracted lots increased to 190k.
The broker points out FY27 guidance will be provided in November, with FY29 revenue, underlying EBITDA, margin and EPS growth targets reaffirmed.
Neutral. Target $3.70.
Target price is $3.70 Current Price is $3.12 Difference: $0.58
If SLC meets the Macquarie target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $3.70, suggesting upside of 11.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.9, implying annual growth of 2775.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 48.0. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.4, implying annual growth of 50.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 31.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SLC as Buy (1) -
First Take: UBS views Superloop's FY26 results as a solid beat, with EBITDA of $123m above guidance and expectations, supported by stronger gross margins and accelerating Consumer subscriber growth.
Operating cash flow was particularly strong at $121m, 15% ahead of the analyst's expectations and consensus, with 101% cash conversion, while capex was only modestly above guidance.
Consumer net adds are viewed as the standout, with recent monthly additions running ahead of forecasts and new order share of 8.8% well above Superloop's 5.2% market share, while FY29 growth ambitions were reiterated.
Buy. Target $4.15.
Target price is $4.15 Current Price is $3.12 Difference: $1.03
If SLC meets the UBS target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $3.70, suggesting upside of 11.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.9, implying annual growth of 2775.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 48.0. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.4, implying annual growth of 50.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 31.8. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SRG SRG GLOBAL LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $3.96
Bell Potter rates SRG as Buy (1) -
Bell Potter maintains a Buy rating for SRG Global with its target price increased to $4.50 from $4.25 following an FY26 result featuring underlying Group EBITDA of $170m, up 34% year-on-year.
The analyst highlights that the robust performance is underpinned by contributions from the TAMS business and accelerated organic growth in Maintenance & Industrial Services.
The broker's estimates adjust FY27 to FY29 revenue and earnings forecasts upward by 2%-8% to reflect higher revenue expectations across segments and an upgraded FY27 EBITDA guidance range of $195m to $205m.
Commentary highlights a strong balance sheet with net debt of $26.5m and robust operating cash flow supported by high cash conversion.
The valuation reflects a premium justified by management's strong track record and a high proportion of recurring earnings streams.
Target price is $4.50 Current Price is $3.96 Difference: $0.54
If SRG meets the Bell Potter target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $4.27, suggesting upside of 4.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 8.50 cents and EPS of 13.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 14.5, implying annual growth of N/A. Current consensus DPS estimate is 8.3, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 28.3. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 9.50 cents and EPS of 15.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.3, implying annual growth of 12.4%. Current consensus DPS estimate is 9.0, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 25.2. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates SRG as Accumulate (2) -
Morgans points to a strong FY26 result from SRG Global with EPS growth of 30%-plus which aligns with the 5-year CAGR of 32%-plus.
The result exceeded June guidance with Maintenance EBITDA up 40% y/y and E&C rising 14%. TAMS achieved better than expected EBITDA annualised results.
FY27 EBITDA guidance lifted by 2%-3% at the mid-point, the analyst notes. The order book has advanced significantly over the last 6 months, up 20%-plus.
Target price rises to $4.70 from $4.20. No change in Accumulate rating.
Target price is $4.70 Current Price is $3.96 Difference: $0.74
If SRG meets the Morgans target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $4.27, suggesting upside of 4.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 8.00 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 14.5, implying annual growth of N/A. Current consensus DPS estimate is 8.3, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 28.3. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 8.50 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.3, implying annual growth of 12.4%. Current consensus DPS estimate is 9.0, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 25.2. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SSM SERVICE STREAM LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.53
UBS rates SSM as Buy (1) -
First Take: Service Stream delivered a better-than-expected FY26 result, with EBITDA 4% ahead of UBS and consensus, driven by strong Asset & Facility Management earnings and improving Utilities margins, partly offset by weaker Telco.
Cash conversion was strong at 114%, while work in hand remained robust at $8.2bn, with 85% of FY27 work secured under contracts or extension options.
The analyst is encouraged by utilities margins reaching 6% in 2H26 and the positive contribution from defence, while management reiterated expectations for 5%–10% annual earnings growth and appears increasingly open to M&A opportunities, the broker comments.
Buy. Target $2.85.
Target price is $2.85 Current Price is $2.53 Difference: $0.32
If SSM meets the UBS target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $2.75, suggesting upside of 5.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 6.00 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.8, implying annual growth of 11.8%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 24.2. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 7.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.9, implying annual growth of 19.4%. Current consensus DPS estimate is 6.9, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 20.2. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates STO as Buy (1) -
First Take: Santos reported 1H26 underlying EBITDA of US$1.57bn, around 1% ahead of Citi and consensus, while underlying earnings of US$397m beat the broker by 13% and consensus by 17%, largely due to a lower tax expense.
The US10.6c interim dividend was ahead of consensus and represented a 100% payout of operating free cash flow, which is viewed as an encouraging signal ahead of the new capital management framework expected with the February result.
Positively, the analyst explains there is ongoing de-risking across Santos' growth portfolio, with Barossa maintaining its targeted eight-day cargo loading cadence, Pikka ramping up and Papua LNG remaining on track for FID in 4Q26.
Calendar 2026 production, sales and cost guidance is unchanged.
Buy rating. Target $8.30.
Target price is $8.30 Current Price is $8.11 Difference: $0.19
If STO meets the Citi target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $8.14, suggesting downside of -2.2% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 39.38 cents and EPS of 70.01 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 62.0, implying annual growth of N/A. Current consensus DPS estimate is 35.9, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 13.4. |
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 75.85 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.9, implying annual growth of -0.2%. Current consensus DPS estimate is 44.7, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 13.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates STO as Outperform (1) -
First Impressions: A stronger-than-expected bottom-line result and interim dividend highlighted Santos' 1H26 performance, with underlying NPAT of US$397m well ahead of Macquarie and consensus despite underlying EBITDAX of US$1.6bn being broadly in line.
The US11.6c interim dividend represented around 100% of 1H26 free cash flow from operations, while all calendar 2026 guidance was maintained.
The analyst highlights de-leveraging as the next focus, with Santos reiterating its US$2.5bn net debt reduction target by 2030. Barossa is producing ahead of the broker's expectations in 3Q26, Pikka is ramping up and Papua LNG remains on track for FID in 4Q26.
Outperform rated. Target $9.05.
Target price is $9.05 Current Price is $8.11 Difference: $0.94
If STO meets the Macquarie target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $8.14, suggesting downside of -2.2% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 30.05 cents and EPS of 51.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 62.0, implying annual growth of N/A. Current consensus DPS estimate is 35.9, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 13.4. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 38.94 cents and EPS of 42.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.9, implying annual growth of -0.2%. Current consensus DPS estimate is 44.7, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 13.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates STO as Buy (1) -
First Take: A stronger-than-expected interim dividend was the highlight of Santos' 1H26 result, with the USD11.6cps payout 10% ahead of consensus and representing 100% of free cash flow from operations, UBS explains.
Underlying NPAT of US$397m was in line with expectations and 18% ahead of consensus, while EBITDAX was slightly weaker on higher costs.
UBS views the dividend as signalling confidence in a stronger 2H26, with deleveraging and the ramp-up of Barossa and Pikka now key alongside a potential Papua LNG FID in 4Q26.
Buy. Target $8.30.
Target price is $8.30 Current Price is $8.11 Difference: $0.19
If STO meets the UBS target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $8.14, suggesting downside of -2.2% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 48.13 cents and EPS of 68.55 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 62.0, implying annual growth of N/A. Current consensus DPS estimate is 35.9, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 13.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 52.51 cents and EPS of 72.93 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.9, implying annual growth of -0.2%. Current consensus DPS estimate is 44.7, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 13.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SXL SOUTHERN CROSS MEDIA GROUP LIMITED
Print, Radio & TV
More Research Tools In Stock Analysis - click HERE
Overnight Price: $0.57
Morgan Stanley rates SXL as Underweight (5) -
While the integration of Southern Cross Media and Seven West Media is running on schedule and the pace of cost-out is ahead, Morgan Stanley doesn't believe the combination is the remedy to the structural decline that lies ahead for this portfolio of traditional TV/radio/print assets.
Assuming the merger was in place for a full 12 months, pro forma group FY26 revenue declined by -4.5% and pro forma earnings declined -13%, the broker notes.
The positive news is $30m of the merger synergy target has been realised (one year ahead) with a new target to take out costs of $145m-$150m. But over the next three years, Morgan Stanley forecasts a new Southern Cross earnings CAGR of -7%.
Target falls to 50c from 65c, Underweight retained. Industry view: Attractive.
Target price is $0.50 Current Price is $0.57 Difference: minus $0.075 (current price is over target).
If SXL meets the Morgan Stanley target it will return approximately minus 13% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $0.61, suggesting upside of 8.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.1, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 6.2. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 0.00 cents and EPS of 9.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 7.1, implying annual growth of -22.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 7.9. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.31
Citi rates TLC as Sell (5) -
First Take: Lottery Corp's FY26 underlying EBIT was in line with Citi's forecast and –1% below consensus.
Lotteries and Keno EBIT met expectations. Powerball like-for-like sales are noted as rising 10.5% post the price rise, but the analyst is more interested in the exit rate as sales have been slowing in the last six months to 6%-plus.
The Powerball and Oz Lotto jackpot outcomes were seen as a 1 in 45 year event, the analyst states, which affected turnover by around –$700m and weighed on like-for-like sales.
FY27 open guidance is in line with the broker's forecast. Overall, the result is considered broadly in line.
Target $5.
Target price is $5.00 Current Price is $5.31 Difference: minus $0.31 (current price is over target).
If TLC meets the Citi target it will return approximately minus 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $5.86, suggesting upside of 9.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 16.50 cents and EPS of 15.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.6, implying annual growth of -5.1%. Current consensus DPS estimate is 16.4, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 34.3. |
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 16.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.4, implying annual growth of 11.5%. Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 30.7. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates TLC as Outperform (1) -
Initial Impressions: Lottery Corp's FY26 NPAT of $343m was down 6% y/y, and -2% below Macquarie and consensus, as unfavourable jackpot outcomes reduced revenue by -$350m, partly offset by better-than-expected cost control.
FY27 operating cost guidance of -$305m-$315m is below the analyst's forecast and broadly in line with consensus, while leverage is expected to rise following the $1.15bn Victorian lotteries licence payment.
The broker expects normalised jackpot activity to support a recovery in FY27 lottery volumes, supplemented by game and pricing changes, and views the business as fundamentally robust.
Macquarie would be a buyer on weakness, looking through short-term jackpot-related earnings revisions.
Target price is $6.00 Current Price is $5.31 Difference: $0.69
If TLC meets the Macquarie target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $5.86, suggesting upside of 9.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 16.00 cents and EPS of 16.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.6, implying annual growth of -5.1%. Current consensus DPS estimate is 16.4, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 34.3. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 18.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.4, implying annual growth of 11.5%. Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 30.7. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TPW TEMPLE & WEBSTER GROUP LIMITED
Furniture & Renovation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $5.05
Citi rates TPW as Neutral (3) -
In an early take, Citi assesses a strong FY26 result today by Temple & Webster but a weak FY27 trading update, increasing reliance on sustainable margin improvement.
FY26 earnings (EBITDA) of $21.9m exceeded the $20.5m consensus forecast, the analysts observe, while the fourth-quarter earnings margin reached around 6% versus 3.3% for FY26.
Revenue fell -13% on the prior year from July 1 to August 17, although contribution margin dollars rose 10%, the broker explains.
FY27 earnings guidance of $33m–$40m implies to Citi around 50%–80% growth, driven by better unit economics and operating leverage.
Target $5.60. Neutral rating.
Target price is $5.60 Current Price is $5.05 Difference: $0.55
If TPW meets the Citi target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $6.31, suggesting upside of 52.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.6, implying annual growth of -30.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 62.9. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents and EPS of 19.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.2, implying annual growth of 130.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 27.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates TPW as Neutral (3) -
First Take: UBS notes margin improvement was the standout despite a softer FY26 top line for Temple & Webster, with underlying EBITDA beating expectations and 4Q26 EBITDA margins reaching 6% as contribution margins strengthened.
Early FY27 revenue has fallen -13% y/y, but contribution margins improved 10%, reinforcing management's focus on profitability over growth.
FY27 EBITDA guidance of $33m-$40m is above UBS at the midpoint despite implying broadly flat revenue, although the analyst expects the weak revenue momentum to remain an investor concern.
Neutral. Target $6.10.
Target price is $6.10 Current Price is $5.05 Difference: $1.05
If TPW meets the UBS target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $6.31, suggesting upside of 52.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.6, implying annual growth of -30.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 62.9. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.2, implying annual growth of 130.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 27.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $7.76
UBS rates WHC as Neutral (3) -
First Take: Whitehaven Coal's FY26 result was broadly in line, with EBITDA slightly below UBS and consensus, while underlying NPAT of $227m was weaker than expected.
Operational delivery was strong, with production and sales at or above guidance and unit costs down -5% to $132/t.
Net debt of $1.33bn was better than forecast and the 10cps dividend was supplemented by a further $47m buyback.
FY27 guidance is viewed as conservative, with saleable coal volumes declining around -3% at the midpoint and unit costs rising around 6%, while higher capex also weighs on the near-term outlook.
Neutral. Target $8.
Target price is $8.00 Current Price is $7.76 Difference: $0.24
If WHC meets the UBS target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $8.66, suggesting upside of 14.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 14.00 cents and EPS of 40.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 34.5, implying annual growth of -57.4%. Current consensus DPS estimate is 15.7, implying a prospective dividend yield of 2.1%. Current consensus EPS estimate suggests the PER is 22.0. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 22.00 cents and EPS of 85.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.7, implying annual growth of 64.3%. Current consensus DPS estimate is 22.6, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 13.4. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Today's Price Target Changes
| Company | Last Price | Broker | New Target | Prev Target | Change | |
| AEL | Amplitude Energy | $1.64 | Macquarie | 2.45 | 2.15 | 13.95% |
| Ord Minnett | 2.55 | 2.65 | -3.77% | |||
| AHL | Adrad | $1.25 | Bell Potter | 1.40 | 1.35 | 3.70% |
| APZ | Aspen Group | $5.25 | Bell Potter | 6.65 | 6.50 | 2.31% |
| Citi | 6.10 | 5.40 | 12.96% | |||
| AUC | Ausgold | $1.29 | Bell Potter | 1.50 | 1.70 | -11.76% |
| BEN | Bendigo & Adelaide Bank | $10.41 | Ord Minnett | 11.00 | 11.50 | -4.35% |
| BHP | BHP Group | $63.71 | Macquarie | 58.50 | 55.00 | 6.36% |
| Morgan Stanley | 67.50 | 67.00 | 0.75% | |||
| Morgans | 55.30 | 59.80 | -7.53% | |||
| Ord Minnett | 63.00 | 61.00 | 3.28% | |||
| BRG | Breville Group | $31.44 | Citi | 39.65 | 39.85 | -0.50% |
| BSL | BlueScope Steel | $32.15 | Macquarie | 34.35 | 35.95 | -4.45% |
| CGF | Challenger | $9.80 | Citi | 11.55 | 11.90 | -2.94% |
| Macquarie | 10.20 | 10.30 | -0.97% | |||
| COH | Cochlear | $137.52 | Citi | 140.00 | 100.00 | 40.00% |
| Macquarie | 124.00 | 115.00 | 7.83% | |||
| Ord Minnett | 145.80 | 133.00 | 9.62% | |||
| UBS | 150.00 | 106.00 | 41.51% | |||
| CSL | CSL | $166.48 | Bell Potter | 150.00 | 120.00 | 25.00% |
| Citi | 160.00 | 110.00 | 45.45% | |||
| Macquarie | 133.00 | 108.00 | 23.15% | |||
| Morgan Stanley | 172.00 | 163.00 | 5.52% | |||
| Morgans | 187.71 | 147.59 | 27.18% | |||
| Ord Minnett | 152.50 | 123.30 | 23.68% | |||
| UBS | 181.00 | 158.00 | 14.56% | |||
| DRR | Deterra Royalties | $4.44 | UBS | 4.50 | 4.75 | -5.26% |
| HCW | HealthCo Healthcare & Wellness REIT | $0.72 | Bell Potter | 0.90 | 0.95 | -5.26% |
| Morgan Stanley | 0.75 | 0.70 | 7.14% | |||
| Morgans | 0.85 | 0.95 | -10.53% | |||
| HUB | Hub24 | $79.46 | Bell Potter | 90.00 | 110.00 | -18.18% |
| Citi | 93.50 | 95.00 | -1.58% | |||
| Ord Minnett | 93.00 | 95.00 | -2.11% | |||
| UBS | 83.50 | 86.00 | -2.91% | |||
| IGO | IGO Ltd | $7.90 | Macquarie | 9.50 | 10.50 | -9.52% |
| IRE | Iress | $6.09 | Ord Minnett | 11.30 | 11.60 | -2.59% |
| JDO | Judo Capital | $1.01 | Macquarie | 1.65 | 1.55 | 6.45% |
| Morgan Stanley | 1.30 | 1.25 | 4.00% | |||
| Morgans | 1.42 | 1.47 | -3.40% | |||
| LLC | Lendlease Group | $2.76 | Citi | 3.10 | 4.50 | -31.11% |
| PLS | PLS Group | $4.78 | Macquarie | 6.00 | 6.25 | -4.00% |
| PME | Pro Medicus | $197.84 | Ord Minnett | 230.00 | 210.00 | 9.52% |
| PXA | Pexa Group | $7.92 | UBS | 9.00 | 9.80 | -8.16% |
| RGN | Region Group | $2.26 | Bell Potter | 2.55 | 2.60 | -1.92% |
| RWC | Reliance Worldwide | $4.38 | Citi | 4.75 | 3.90 | 21.79% |
| Macquarie | 4.75 | 4.90 | -3.06% | |||
| Morgans | 4.62 | 3.60 | 28.33% | |||
| Ord Minnett | 4.75 | 4.00 | 18.75% | |||
| SGM | Sims | $22.67 | Macquarie | 35.10 | 34.40 | 2.03% |
| SKS | SKS Technologies | $8.73 | Morgans | 9.80 | 9.40 | 4.26% |
| SKY | Sky Metals | $0.23 | Morgans | 0.40 | 0.35 | 14.29% |
| SRG | SRG Global | $4.10 | Bell Potter | 4.50 | 4.25 | 5.88% |
| Morgans | 4.70 | 4.20 | 11.90% | |||
| SXL | Southern Cross Media | $0.56 | Morgan Stanley | 0.50 | 0.65 | -23.08% |
Summaries
| AEL | Amplitude Energy | Outperform - Macquarie | Overnight Price $1.65 |
| Buy - Ord Minnett | Overnight Price $1.65 | ||
| AHL | Adrad | Upgrade to Buy from Hold - Bell Potter | Overnight Price $1.22 |
| AIA | Auckland International Airport | Neutral - Citi | Overnight Price $7.25 |
| APA | APA Group | Buy - Citi | Overnight Price $10.01 |
| APZ | Aspen Group | Buy - Bell Potter | Overnight Price $5.38 |
| Buy - Citi | Overnight Price $5.38 | ||
| AUC | Ausgold | Downgrade to Speculative Hold from Speculative Buy - Bell Potter | Overnight Price $1.33 |
| BEN | Bendigo & Adelaide Bank | Sell - Citi | Overnight Price $10.56 |
| Underperform - Macquarie | Overnight Price $10.56 | ||
| Underweight - Morgan Stanley | Overnight Price $10.56 | ||
| Downgrade to Hold from Accumulate - Ord Minnett | Overnight Price $10.56 | ||
| BHP | BHP Group | Neutral - Macquarie | Overnight Price $63.85 |
| Overweight - Morgan Stanley | Overnight Price $63.85 | ||
| Downgrade to Trim from Hold - Morgans | Overnight Price $63.85 | ||
| Hold - Ord Minnett | Overnight Price $63.85 | ||
| BRE | Brazilian Rare Earths | Speculative Buy - Ord Minnett | Overnight Price $4.30 |
| BRG | Breville Group | Buy - Citi | Overnight Price $33.10 |
| Buy - UBS | Overnight Price $33.10 | ||
| BSL | BlueScope Steel | Downgrade to Neutral from Outperform - Macquarie | Overnight Price $31.50 |
| BWP | BWP Trust | Buy - Citi | Overnight Price $3.75 |
| Neutral - UBS | Overnight Price $3.75 | ||
| CGF | Challenger | Buy - Citi | Overnight Price $10.32 |
| Neutral - Macquarie | Overnight Price $10.32 | ||
| Neutral - UBS | Overnight Price $10.32 | ||
| CGS | Cogstate | Buy - Bell Potter | Overnight Price $2.73 |
| COH | Cochlear | Upgrade to Neutral from Sell - Citi | Overnight Price $141.20 |
| Neutral - Macquarie | Overnight Price $141.20 | ||
| Equal-weight - Morgan Stanley | Overnight Price $141.20 | ||
| Hold - Ord Minnett | Overnight Price $141.20 | ||
| Neutral - UBS | Overnight Price $141.20 | ||
| CSL | CSL | Hold - Bell Potter | Overnight Price $157.82 |
| Neutral - Citi | Overnight Price $157.82 | ||
| Neutral - Macquarie | Overnight Price $157.82 | ||
| Overweight - Morgan Stanley | Overnight Price $157.82 | ||
| Buy - Morgans | Overnight Price $157.82 | ||
| Hold - Ord Minnett | Overnight Price $157.82 | ||
| Buy - UBS | Overnight Price $157.82 | ||
| DRR | Deterra Royalties | Neutral - Macquarie | Overnight Price $4.35 |
| Neutral - UBS | Overnight Price $4.35 | ||
| EBO | Ebos Group | Buy - Citi | Overnight Price $18.23 |
| EVN | Evolution Mining | Neutral - Citi | Overnight Price $13.65 |
| Neutral - Macquarie | Overnight Price $13.65 | ||
| FBU | Fletcher Building | Neutral - Citi | Overnight Price $3.08 |
| GOZ | Growthpoint Properties Australia | Buy - Citi | Overnight Price $2.12 |
| HCW | HealthCo Healthcare & Wellness REIT | Buy - Bell Potter | Overnight Price $0.73 |
| Underweight - Morgan Stanley | Overnight Price $0.73 | ||
| Speculative Buy - Morgans | Overnight Price $0.73 | ||
| HSN | Hansen Technologies | Buy - UBS | Overnight Price $4.25 |
| HUB | Hub24 | Downgrade to Hold from Buy - Bell Potter | Overnight Price $79.94 |
| Buy - Citi | Overnight Price $79.94 | ||
| Overweight - Morgan Stanley | Overnight Price $79.94 | ||
| Accumulate - Ord Minnett | Overnight Price $79.94 | ||
| Neutral - UBS | Overnight Price $79.94 | ||
| IMD | Imdex | Upgrade to Buy from Hold - Ord Minnett | Overnight Price $3.75 |
| IRE | Iress | Buy - Ord Minnett | Overnight Price $6.40 |
| JDO | Judo Capital | Buy - Citi | Overnight Price $1.07 |
| Outperform - Macquarie | Overnight Price $1.07 | ||
| Overweight - Morgan Stanley | Overnight Price $1.07 | ||
| Buy - Morgans | Overnight Price $1.07 | ||
| Neutral - UBS | Overnight Price $1.07 | ||
| LLC | Lendlease Group | Downgrade to Neutral from Buy - Citi | Overnight Price $2.80 |
| MGR | Mirvac Group | Buy - Citi | Overnight Price $1.74 |
| Neutral - UBS | Overnight Price $1.74 | ||
| MP1 | Megaport | Buy - Citi | Overnight Price $20.84 |
| PME | Pro Medicus | Buy - Bell Potter | Overnight Price $196.75 |
| Accumulate - Morgans | Overnight Price $196.75 | ||
| Buy - Ord Minnett | Overnight Price $196.75 | ||
| PXA | Pexa Group | Outperform - Macquarie | Overnight Price $7.88 |
| Neutral - UBS | Overnight Price $7.88 | ||
| RGN | Region Group | Buy - Bell Potter | Overnight Price $2.31 |
| Buy - Citi | Overnight Price $2.31 | ||
| Underweight - Morgan Stanley | Overnight Price $2.31 | ||
| Neutral - UBS | Overnight Price $2.31 | ||
| RWC | Reliance Worldwide | Neutral - Citi | Overnight Price $4.50 |
| Outperform - Macquarie | Overnight Price $4.50 | ||
| Equal-weight - Morgan Stanley | Overnight Price $4.50 | ||
| Hold - Morgans | Overnight Price $4.50 | ||
| Hold - Ord Minnett | Overnight Price $4.50 | ||
| SGM | Sims | Outperform - Macquarie | Overnight Price $22.97 |
| Equal-weight - Morgan Stanley | Overnight Price $22.97 | ||
| SGP | Stockland | Buy - Citi | Overnight Price $4.05 |
| Neutral - UBS | Overnight Price $4.05 | ||
| SKS | SKS Technologies | Accumulate - Morgans | Overnight Price $8.57 |
| SKY | Sky Metals | Speculative Buy - Morgans | Overnight Price $0.21 |
| SLC | Superloop | Buy - Citi | Overnight Price $3.12 |
| Neutral - Macquarie | Overnight Price $3.12 | ||
| Buy - UBS | Overnight Price $3.12 | ||
| SRG | SRG Global | Buy - Bell Potter | Overnight Price $3.96 |
| Accumulate - Morgans | Overnight Price $3.96 | ||
| SSM | Service Stream | Buy - UBS | Overnight Price $2.53 |
| STO | Santos | Buy - Citi | Overnight Price $8.11 |
| Outperform - Macquarie | Overnight Price $8.11 | ||
| Buy - UBS | Overnight Price $8.11 | ||
| SXL | Southern Cross Media | Underweight - Morgan Stanley | Overnight Price $0.57 |
| TLC | Lottery Corp | Sell - Citi | Overnight Price $5.31 |
| Outperform - Macquarie | Overnight Price $5.31 | ||
| TPW | Temple & Webster | Neutral - Citi | Overnight Price $5.05 |
| Neutral - UBS | Overnight Price $5.05 | ||
| WHC | Whitehaven Coal | Neutral - UBS | Overnight Price $7.76 |
RATING SUMMARY
| Rating | No. Of Recommendations |
| 1. Buy | 48 |
| 2. Accumulate | 4 |
| 3. Hold | 40 |
| 4. Reduce | 1 |
| 5. Sell | 7 |
Wednesday 19 August 2026
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
| 1 |
The Market In Numbers – 21 Nov 2026Nov 21 2026 - Australia |
| 2 |
ASX Winners And Losers Of Today – 20-11-26Nov 20 2026 - Daily Market Reports |
| 3 |
FNArena Corporate Results Monitor – 20-11-2026Nov 20 2026 - Australia |
| 4 |
Next Week At A Glance – 23-27 Nov 2026Nov 20 2026 - Weekly Reports |
| 5 |
Weekly Top Ten News Stories – 20 November 2026Nov 20 2026 - Weekly Reports |

